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ABSTRACT OF DISSERTATION
CELL SURFACE COATINGS FOR MAMMALIAN CELL-BASED THERAPEUTIC
DELIVERY
The cell plasma membrane is an interactive interface playing an important role in
regulating cell-to-cell, cell-to-tissue contact, and cell-to-environment responses. This
environment-responsive phospholipid layer consisting of multiple dynamically balanced
macromolecules, such as membrane proteins, carbohydrate and lipids, is regarded as a
promising platform for various surface engineering strategies. Through different chemical
modification routes, we are able to incorporate various artificial materials into the cell
surface for biomedical applications in small molecule and cellular therapeutics.
In this dissertation, we establish two different cell coating techniques for
applications of cell-mediated drug delivery and the localization of cell-based therapies to
specific tissues. The first part of this dissertation establishes a membrane-associated
hydrogel patch for drug delivery. The crosslinking of a grafted polymeric patch from a
mammalian cell membrane is achieved through surface-mediated photolithographic
polymerization. With the use of photomask, the formation of nanoparticle-loaded
PEGDA hydrogel is controlled to deposit various geometric features on photoinitiatorimmobilized surfaces. Through microarray patch patterning, we analyzed the influence of
processing parameters on the accuracy of polymer patterning on a microarray. We then
optimized the patterning approach for the formation of PEGDA patches on live A549
cells.
In the second part of this dissertation, we study the use of tissue-adhesive coatings
to improve the retention of therapeutic mesenchymal stem cells (MSCs) in the heart
following intramyocardial or intravenous injection. MSCs were coated with antibodies
against ICAM1 to adhere to CAM-overexpressed endothelium present in the heart
following MI. Through intramyocardial or intravenous delivery, we observe higher
number of coated cells retained in the heart over uncoated ones, supporting enhanced
affinity for the inflamed endothelium near the infarct. We correlate the detachment force
of antigen-interacted MSCs by a parallel laminar flow assay with the density of ICAM on
the substrate and the density of anti-ICAM on the MSC surface. MSC retention on CAMmodified surfaces or activated HUVECs was significantly increased on antibody-coated
groups (~90%) under physiologically hemodynamic forces (< 30dyne/cm 2), compared to
uncoated MSCs (~20%). Moreover, a dramatic reduction of immune cell quantity was
observed after intravenous injection, indicating the enhanced immunoregulatory efficacy
by systemically delivering ICAM-adhesive MSCs to the site of inflammation.
KEYWORDS: cell surface coating, hydrogel patch, surface-mediated polymerization,
antibody incorporation, endothelium targeting, biotin streptavidin affinity
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CHAPTER 1. TECHNIQUES FOR COATING MAMMALIAN CELLS

1.1

Introduction: roles of cell surface engineering
Cell membrane is a complex phospholipid bilayer covered by a variety of biological

components including glycolipids, proteins and carbohydrate chains. This biointeractive
interface not only acts as a safeguard against unwanted intruders but also governs the
communication and essential nutrient exchanges between inner and outer region of a cell.
Given diverse biological moieties displayed on the surfaces of different cell types,
engineering the surface of a cell provides huge potentials to transform the intrinsic
functions and activities of cell surface components to match specific therapeutic targets or
biomedical needs.
Cell surfaces are composed of diverse biochemical and are characterized to achieve
exclusive functions through both genetic and non-genetic techniques. Recently, the first
therapy based on the genetic modification of a cell surface was approved by the FDA, and
the delivery of chimeric antigen receptor-modified (CAR) T-cells is now used clinically
for blood cancers such as leukemia and melanoma. T cells are collected from a patient’s
blood are genetically reprogrammed by gene sequence insertion using inactive viral
vectors. The genetic manipulation enables reprogramming of T cell surface structure by
expressing tumor antigen-recognized CAR for targeting cancer cell antigen [1].
However, challenges of genetic cell surface manipulation remain [2]. Firstly,
genetic modification methods do not really induce the expression of desired substances,
limiting the coating choices on cells. Secondly, genetic manipulation is subject to low
transfection efficiencies, where the fraction of cells showing any significant change in
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properties is significantly less than one. Beyond the efficiency, the genetically-engineered
cells require time for transcription and protein synthesis, requiring hours to days for
surface modification. Finally, there are still significant concerns over the safety of viral
transfection approaches, and modern non-viral methods lag behind viral methods in
transfection efficiency and cell toxicity. As a result, this dissertation broadly focuses on
non-genetic strategies for cell surface modification of functional mammalian cells. Cell
surface coating can perform unique biological functionalities that cells inherently lack. In
our work, the engineered cells are capable of carrying drug payload for cell mediated drug
delivery or selectively targeting tissues of interest for local cell retention in the heart, while
maintaining their intrinsic cellular properties to interact with extracellular environment.
Here, we describe the current strategies for non-genetic cell surface engineering. They are
broadly divided into covalent and non-covalent approaches, and this chapter contrasts the
strengths and weaknesses of each approach.

1.2

Current non-genetic cell surface engineering technologies: non-covalent
interaction
To alter the intrinsic functionalities of cell surfaces by non-genetic methods, non-

covalent and covalent bonds are two main categories of molecular binding and are widely
used to attach biomaterial coatings on cell surfaces (Figure 1.1). Non-covalent binding
includes electrostatic interactions, hydrogen bonds, ionic bonds and van der Waals
interactions, and has relatively weak binding energy which can possibly be broken by
molecule activities at physiological conditions; however, noncovalent interactions are still
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considered as critical modification processes to regulate cell surface protein-protein
interactions and cell membrane dynamics.
1.2.1

Cell surface coating through electrostatic interactions

The extracellular composition of glycoprotein and glycolipid residues on a cell
membrane exposes negative ions provided from oligosaccharides, driving the cell plasma
membrane to be a negatively charged interface that electrostatically attracts essential
cations for normal cellular functions. For cell surface coating, the peripheral membrane’s
negative charge can be regarded as an adhesive surface for non-covalent deposition of
positively charged materials, such as polycationic peptides, proteins, polymers or
nanoparticles (Figure 1.2).
Notably, the fabrication of polyionic polymers through layer-by-layer (LbL)
techniques offers a direct method for creating a cytoprotective coating. Through sequential
deposition of oppositely charged polyelectrolyte layers, a multilayer polymer thin film is
directly form on the surface of each individual cell. From Tabrizian’s lab, alternative
coating of anionic AL and cationic PLL polyelectrolyte on red blood cells (RBC) generated
universal RBCs that are not immunologically recognized by immunotargeting [3]. This
multilayer encapsulation on RBCs protected cells from antibody-A capture and showed no
aggregation caused by immunorecognition after introducing antibody-A, supporting a
strong reduction in immunogenicity and antigenicity of blood group antigens.
Additionally, coated cells maintained their oxygen carrying capacity and also released
amounts of ATP and hemoglobin consistent with the low levels of cell death of seen in
uncoated cells [3]. Similarly, absorption of polycationic PEI mixed with silica
nanoparticles, considered as an artificially protective cell wall, on negatively charged

3

mammalian cell membrane (HeLa, NIH 3T3 fibroblast and Jurkat) demonstrated coatingbased cytoprotection from enzyme-induced cell apoptosis [4]. Another group has exploited
LbL deposition of PLL(+)/HA(-) nanolayers to form a protective coating on mesenchymal
stem cell (MSC) cell membrane without affecting cell morphology, showing the material
absorption potential on MSCs through electrostatic attraction. However, the long term
viability of PLL-encapsulated MSCs began to decrease after several days [5].
While most studies utilize polyelectrolyte materials like PLL [3, 5], PAH [6, 7] and
PEI [4], Germain M et al. have proposed PDADMAC/PSS as a more biocompatible LbL
polymer coating on MELN breast cancer cells. The cell-associated PDADMAC coating
showed three-fold higher on cell viability than the use of PLL, PAH and PEI. In addition,
PDADMAC-coated cells demonstrated cytoprotection from macromolecular by
prohibiting the internalization of 60kDa and 80kDa proteins [8].
In all, electrostatic deposition of polymeric materials provides a simple and rapid
method for coating the charged surface of a cell [6, 7, 9, 10]. While the coating of
polycation polymer can protect cells from unfavorable molecule invasion, the charged
covering that is always destructive for cells could certainly compromise the fragile nature
of mammalian cell membrane, limiting its use for long-term cell activities.
1.2.2

Cell surface coating through hydrophobic lipid interactions

Lipids are broadly used materials for protein conjugation and drug delivery due to
their biocompatibility and controllable structural properties for a variety of
bioconjugations. Here, they are considered as a cell surface coating material to conjugate
specific bioactive molecules on the surface of living cells for specific targeting purposes.
Due to poor water solubility of lipid tail, PEGylation is widely employed to create
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amphiphilic PEG-derivative lipids for cell plasma membrane modification. Namagune’s
group [11] demonstrated the stable grafting of single lipid tailed oleyl‐PEG-biotin or
double lipid tailed-DOPE‐PEG-FITC on surfaces of human and sheep erythrocytes.
Because of the coverage of lipid tails anchored onto plasma membranes, DOPE-modified
cells showed the great antigen masking efficiency to escape from the recognition of
antibody against A antigen on erythrocytes.
Moreover, the uses of protein-conjugated lipids to incorporate non-naturally and
non-abundantly expressed proteins on MSC surfaces were exhibited by Bull’s group.
Varying molecular weights of PEG groups were used to support [12, 13] the high viability
of coated MSCs after phospholipid modification. MSCs were designed for targeting
specific MSC homing factors using lipid-PEG conjugates with terminal targeting groups.
Ligand protein SDF-1 and its cognate receptor CXCR4 are known as MSC recruiting
factors, and these were conjugated on the distinct functionalized ends of two different
PEGylated DMPE lipid using NHS [13] or maleimide [12] conjugation. The surfacecoating of CXCR4 or SDF-1 enhanced the MSC migration toward its corresponding
homing target to support the potential CXCR4/SDF1-directed MSC recruitment into
ischemic myocardium by this protein-phospholipid cell surface coating. In addition,
homing peptide CRPPR-grafted phospholipid (DMPE-PEG-CRPPR), conjugated through
the reaction between lipid-maleimide and cysteine-containing peptide, was also
hydrophobically embedded onto MSC surfaces. It indicated that by increasing the amount
of intercalated homing peptide, the number of coated MSCs that migrated to the gradient
of target protein CRIP2 also increased [13].
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Other than synthetic lipid domains like DMPE or DOPE, multiple studies have
showed the use of naturally-derived lipid products to hydrophobically decorate cell
surfaces. PEGylated glycol chitosan-cholesterol-biotin was intercalated into the surface of
A549 cells and labeled with a fluorescent streptavidin for cell imaging up to 8 hours [14].
The two-step biotinylation via click chemistry was processed by inserting the DBCO
(dibenzocyclooctyne)-labelled cholesterol and DSPE onto RAW 247 macrophage cell
membrane. The cholesterol-anchored cell surfaces gave a greater biotinylation reactivity
than the DSPE phospholipid biotin; moreover, both synthetic and naturally-derived lipid
anchorage exhibited negligible cytotoxic effects on lipid-modified cells [15].
Palmitate acid is another naturally formed saturated fatty acid and is known as its
importance of protein lipidation and localization on cell plasma membranes. Early study
from Peacock’s group has first established the conjugation of antibody with NHSderivative palmitate acid for one step cell surface antibody decoration. The pre-conjugated
antibody-palmitate was hydrophobically intercalated into the membrane of P388D1 cells.
Interestingly, it was found that P388D1 macrophages bearing artificial receptor (antiCRBC) was able to interact with CRBC cells to enhance cell-cell interaction [16]. The
advantage of hydrophobic lipid-anchorage on cell membrane modification is that nonpermanent lipid insertion preserves intrinsic protein properties on plasma membrane and
has less harmful effects on cellular functions. However, the retention of cell surfaceintercalated lipids might decrease over time due to their weak binding. The irreversible
and transient kinetics of lipid-membrane interaction could be simply interfered by the
dynamically fluctuated phospholipid interface. Additionally, lipid breakdown could cause
instability of cell surface structure. The presence of multiple lipid enzymes, in an
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extracellular microenvironment, could naturally digest lipid chains into smaller pieces,
leading to functionality loss of lipidated bioconjugate.
1.2.3

Cell surface coating through antibody-antigen specificity

Every cell population has its unique profile of cell surface markers, allowing
antibody-antigen affinity to drive adhesion to the surface of targeted cells. This targeted
adhesion creates opportunities for specific or nonspecific coupling of ligands to the cell
surface. Most commonly, NHS-ester groups are used to tether biotin [17], horseradish
peroxidase (HRP) [18, 19], magnetic beads [20], nanoparticles [21, 22] and a variety of
fluorophores to antibodies, and this diversity expands the portfolio of potential biological
applications in cell surface coating.
Our lab uses antibody-antigen specificity to purify cells based on markerexpression through antigen-specific lysis [23-25]. An ultrathin hydrogel coating was
grafted

from

the

membrane

of

antigen

positive

cells

by

surface-initiated

photopolymerization. A biotinylated antibody was specifically adhered to antigen-positive
cells in order to support immobilization of a streptavidin-photoinitiator, and crosslinked
coatings were generated through the surfaces of antibody/photoinitiator-conjugated Jurkat
or A549 cells under visible light irradiation. These hydrogel coatings form and protect
only antigen-positive cells from lysis conditions by surfactants or hypotonic solutions. A
similar antigen specific cell coating was reported by Sakai et al to encapsulate antigen
positive cells by enzyme-mediated polymerization [26]. Horseradish peroxidase is a
protein enzyme commonly used to catalytically label antigens in immunohistochemical
staining and ELISAs. HRP is a potent activator for radical polymerization of vinyl
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monomers or aromatic derivatives [27, 28], and HRP was used in this study to selectively
form alginate hydrogel coatings on CD31+ and CD326+ cells [26].
Because antibodies have unique antigen-binding domains to target specific cell
surface markers, researchers have come up with a coating of bispecific antibody on cells
by creating a hybrid combination of two different antibodies. This antibody-fused material
with dual antigen-interacting parts was used to coat the cytotoxic killer cells for cancer
cell targeting. Early work in 1990, Taizo Nitta et al. designed a heterofunctional
monoclonal hybrid that has both CD3 (T cells) and LU246 (glioma cells) targeting
properties by fusing two different SH-reduced antigen-binding fragment (Fab) into one
asymmetric antibody structure. Effectively, the coating of glioma-recognized antibody
hybrid on T effecter cells exhibited the enhanced cytotoxic targeting in glioma cells than
the ones without this immunoconjugate [29]. Additionally, the coating of bispecific
immunostructure on T lymphocyte [30] or cytokine-induced killer cells [31] has showed
improved tumor cell targeting efficacy through different designs of antigen binding
orientation [30, 31]. The dual functional antibody with both CD3 and CD123 recognized
variable domains was used to coat CD3+ effector T lymphocyte. The delivery of T cellconjugated bispecific antibody that has CD123 targeting ability was successfully proved
to effectively eliminate CD123+ leukemia tumor cells [30].
The high selectivity of antibody anchoring presents a significant advantage over
other coating grafting techniques. Critically, there are also several limitations with
antibody supported coatings. Selecting an adequate cell surface marker for coating only
on a target cell could be a tricky issue because 1) the same cell surface proteins might be
expressed on distinct cell lineages and 2) the large variability in expression levels within

8

a single population of cells. In many cases, the antigen’s density is too low to effectively
modification the cell’s surface [23]. Moreover, antibody labeling some surface receptors
will trigger intracellular signaling [32-34] that could lead to unexpected cellular activities.
1.2.4

Cell surface coating through receptor-ligand interactions

Cell surface receptors are specialized transmembrane cellular proteins with unique
tertiary structures that specially respond to corresponding docking ligands. To date,
approaches using ligand-receptor binding affinity has been increasingly investigated in
cell surface modification for specialized cell-responsive interactions. For example, the
binding between hyaluronic acid (HA) ligand and its receptor CD44 is one of the key
regulatory interactions for coating deposition [35]. The inflammatory CD44 upregulation
drives the membranes of immune cells, such as leukocyte, macrophage or monocyte, as
HA-targeted interfaces for the surface loading of polymer drug payload or backpack for
cell-mediated drug delivery and uptake [35, 36].
A multilayer polymer-fabricated backpack loaded with a CD44-adhesive HA
interface was specifically attached to the CD44-expressed leukocyte [37] or macrophage
[38] for long-term based drug carrying. By precisely controlling the material size,
geometry [39] and orientation [40], the coating through this HA-CD44 interaction allowed
the sustaining loading only on living CD44+ leucocytes and lymphocyte B cells with no
further material engulfment. This surface-attached polymeric film was known to increase
cell-cell interaction and communication. The events of cell aggregation were raised in
response to the increase in surface area of CD44 contacting backpacks [39]. Similarly, the
modification of Fe3O4 nanoparticle-loaded backpack through HA-CD44 interaction was
also applied to magnetically control the migration of backpack-adhered B cells [37]. These
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coating examples through ligand-receptor affinity provides a stable surface loading
strategy for cytotoxic killer cells to deliver the drug payload.
While ligand-receptor interaction also offers some cell-targeting specificity, the
opportunity for inadvertent activation requires caution with this approach. Surface binding
on receptor could accelerate internalization of the surface coated materials and decrease
the availability of the surface-loaded materials. Thus, while there are opportunities for
receptor ligand anchoring, the potential for unintended biological responses often
outweigh the benefits of this strategy.
1.2.5

Cell surface engineering through covalent amide bonds

Covalent attachment provides a more stable attachment then noncovalent strategies
through the formation of an irreversible binding to the cell surface. The cell’s peripheral
membrane is composed of numerous structures for covalent binding, including proteins,
phospholipids, and carbohydrate chains. In this dissertation, I commonly conjugate groups
to the cell surface covalently through the formation of an amide bond on cell surface
proteins.
Owing to the hydrophilic nature of amine groups, lysine residues are typically
presented at the external surface of protein, and these residues are convenient for chemical
modification. In this section, we focus on different types of amine-reactive chemistries
used for biomaterial attachment in a physiological environment. One amine crosslinking
strategy is to covalently link cyanuric chloride on cell surface glycoproteins. Blackall et
al. used PEGylated cyanuric chloride to form a PEGylated layer around proteins on red
blood cell to camouflage the cells from parasite invasion and immune recognition [41].
Unfortunately, potential cytotoxicity after surface modification with cyanuric chloride
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limits this covalent binding for cell surface engineering beyond the relatively stable red
blood cells.
NHS ester linker are frequently used to decorate living mammalian cells by forming
stable covalent amide-bonds in mild and slightly alkaline biological conditions (pH 7-8)
[12, 23, 42-47]. In contrast to long metabolic engineering processes for covalent binding,
NHS covalently binds structures to cells in under an hour. This approach has been used to
rapidly tether NHS-DNA ligands to the surface of multiple mammalian cell types,
including T cells, red blood cells and cardiac myoblasts without affecting their intrinsic
cellular phenotypes. These specific cell coatings were then used to rapidly adhere cells to
complementary DNA patterned on a glass surface [42]. Sulfonated NHS derivatives have
increased water solubility and improve biocompatibility for cell surface modification, and
this strategy is used to tether protein-signaling aptamers [43] or biotin [44-46] to the
surfaces of MSCs.
Covalent biotinylation strategy using sulfonated NHS-LC-biotin was also utilized
by Karp’s group to coat biotinylated SLex ligand on MSCs for mimicking leukocyte
extravasation through endothelium. With ligand coating, Karp et al. observed the reduction
of MSC rolling velocity on P-selectin modified surface [44] and the increased MSC
homing to inflamed ear in an inflammation-induced murine model after in vivo vein
injection [45], in contrast to unmodified cells. For drug delivery applications, another
study from Anderson’s lab also employed NHS-ester biotin to load neutravidin
nanoparticles on human mesenchymal stem cells (hMSCs) without changing their
tumoritropic property [46].
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The sulfo-NHS biotin strategy is particularly useful as an adaptable tool for
additional cell surface functionalization. Of particular relevance, our lab demonstrated a
cell encapsulation technique by covalent NHS ester biotinylation [23, 47]. Grafting of the
streptavidin-conjugated photoinititator to a biotinylated cell interface rapidly facilitated
polymerization around individual living cells, allowing the generation of polymer coating
for different application such as cytoprotection [23] or tissue targeting [47].

1.3

Surface-mediated polymerization on individual cells
Building hydrogel thin film through surface initiation provides a great foresight in

surface engraftment of polymeric materials (Figure 1.2). Prior study about individual cell
polymerization has grafted nano-thin polymers on yeast cells by surface-activated ATRP
polymerization to exhibit cytoprotective effects. While this uniformly formed polymer
coating can prevent cell agglutination during E-coli introduction [48], the nonphysiological operating conditions of ATRP system and the demand of transition metal
catalyst CuBr2 could lead to lethal DNA cleavage through the oxidative activation, making
it not suitable for mammalian cell manipulation. Various works in thin film generation
have established the local grafting of acrylate or methacrylic polymer on a photoinitiatorimmobilized surface through radical propagation [49-54]. Previously, Seda Kızılel et al.
designed an eosin-initiated photografting system in combination with co-initiator
triethanolamine (TEA) and accelerator vinyl pyrollidinone (VP) to rapidly form a
polyethylene (glycol) diacrylate (PEGDA) hydrogel film on an eosin-localized surface. By
introducing photon energy from visible light, the excited eosin in triplet state promotes the
formation of eosin radical and a cation TEA radical that is critical for polymer propagation
12

by cleaving acrylate double bond [50]. This eosin-based photocrosslinking system further
provided a significant approach to greatly establish polymer-based amplification for
multiple biological application, such as biodetection assay [51, 52], surface encapsulation
or coating on proteins, living cells or tissues.
Our group has developed the generation of polymerized coating on an eosinimmobilized cell surface (Figure 1.3). Previously, we has demonstrated an antigen-targeted
polymer coating on eosin-localized fixed fibroblast, suggesting the feasibility to create a
dye-loaded film for protein signal amplification on each single cell [55]. This surface free
radical polymerization consisting of PEGDA, TEA and VP was further developed to
deposit an ultrathin hydrogel film on living mammalian cell encapsulation for different
biological purposes. We also examined the feasibility of surface-coated gels to protect
cells from immunoattack by evaluating the transport behavior of dextran particles with
different molecular weights through the antigen-based polymer coating on individual
Jurkat cells. Biotinylated antibody recognition on CD45-expressed Jurkats allowed surface
localization of SAEITC to specifically photocrosslink the PEGDA hydrogel on the living
cell membrane. The results from diffusion assay interpreted that either PEGDA575 or
PEGDA3500 showed complete molecule exclusion of dextran particles with molecular
weight higher than 10kDa, suggesting the ability of PEGDA-coated cells to effectively
reject the immune attack by host antibody [25].
Through this size-dependent exclusion property, a degradable coating of PEG
acrylate monomer was utilized to design an antigen-selective cell sorting system through
antigen-specific lysis (ASL). The coating can protect antigen-positive cells from SDS
surfactant lysis. By specially targeting EpCAM-positive A549 or CD45-positive Jurkat,

13

targeted cells can be collected in high purity (over 90%) and maintain their biological
functions after coating removal [24]. To thoroughly understand the coating efficacy by this
surface-initiated polymerization method, the yields of intact cells using both amineconjugated and antigen-conjugated biotinylation were investigated after SDS lysing
depletion. The cells modified through covalent amine-reacted biotinylation provided at
least ten-fold higher eosin density than antibody-tagged cells, resulting in much higher
yield (20%) than others (1% for antibody-labeled cells and 0.1% for untreated cells). This
evidence clearly showed the role of surface-conjugated eosin is highly dependent on the
polymerization efficiency for this cytoprotective coating [23]. In addition to eosin,
fluorescein appears to be an alternative surface-conjugated photoinitiator in this
photopolymerization coating system. Our lab previously established the PEGDA3500
coating

on

living

A549s

through

SAEITC-based

or

FITC/antibody-based

photopolymerization. Both coating approaches successfully present the cell protection
property under hypotonic conditions [56]. Other than cytoprotective applications, recent
work from us also used surface-polymerized cells to improve stem cell retention following
myocardial infacrtion. A synthetic acrylate gelatin polymer which provides extracellular
tissue adhesion property was generated on the bone marrow cell surface. It was proved
that by creating this gelatin coating, we were able to enhance in vivo cell localization in
the infarcted heart tissues [47]. Importantly, in this dissertation, we will take advantage of
this surface-polymerized operation to create a membrane coating with specific
functionality that cell itself doesn’t possess.
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Figure 1-1. Common methods of anchoring coating to a mammalian cell surface.
Reprinted from [57], Copyright 2019, with permission from Springer Nature.
(https://doi.org/10.1186/s13036-018-0131-6)
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Figure 1-2. Material systems for coatings on mammalian cell surfaces. Reprinted from
[57],
Copyright
2019,
with
permission
from
Springer
Nature.
(https://doi.org/10.1186/s13036-018-0131-6)
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Figure 1-3. The generation of polymer coating on living cell surface through surfacemediated polymerization. The images were obtained from smart servier medical art
(https://smart.servier.com/).
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CHAPTER 2. CELL SURFACE COATING DESIGNED FOR DRUG DELIVERY
2.1

Introduction
The human body is a complex bioreactor where an intricate chemical balance is

maintained through passive and active transport. Modern drug delivery systems have been
successful in leveraging our passive transport mechanisms to deliver drugs through the
airways, circulatory system, and diverse tissues. Only recently has the research community
started to utilize the active transport mechanisms for cell-directed transport of species in
the body. Cell-mediated delivery is a revolutionary approach to exploiting natural cell
behaviors, which include migration across biological barriers and targeted homing to
tumors or sites of inflammation [58-61]. Cellular coatings are emerging as a promising
approach for the delivery of a therapeutic payload to a specific site. Therapeutic cargo is
attached to the plasma membrane of tissue-targeting transporter cells to enhance sitespecific delivery. Here, the chapter highlight the opportunities enabled by the recent
clinical and preclinical studies which coated transporter cells are being used for drug
delivery applications.
This section will focus on designing cell coatings for the specific applications in
drug delivery. The following content presents a minor adjustment of our previously
published review article on the journal of biological engineering.
Kara A. Davis,# Pei-Jung Wu,# Calvin F. Cahall, Cong Li, Anuhya Gottipati, and Brad
J. Berron. Coatings on mammalian cells: interfacing cells with their environment.
Journal of Biological Engineering, 2019. 13(1): p. 5. (# equal contribution)
(https://doi.org/10.1186/s13036-018-0131-6)
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2.2

Coating designed to modulate the immune system
In many autoimmune diseases, immune cells mistakenly identify beneficial cells as

a harmful species, resulting in chronic inflammation. In the case of multiple sclerosis
(MS), cellular coatings have been designed to introduce immunologically-active
substances, preventing the immune cells from attacking the normal nerve cells near the
site of the brain and spinal cord [62]. A recent clinical study demonstrated the feasibility
of antigen-specific tolerance therapy by intravenously transporting antigen-mimicking
cells to T cell [63]. For MS, autologous peripheral blood mononuclear cells are coated
with myelin antigens are used to stimulate antigen tolerance through interaction with
myelin-specific T cells. For early stage patients treated with myelin coated cells, the vital
signs and the blood cell composition of the patients were stable and no relapse occurred
within 3 months of treatment.
Similar cell coatings were designed to target and deplete the specific T cell
populations responsible for diabetic injury [64]. ERY1 peptide linkers were used to coat
the surface of erythrocytes with a foreign ovalbumin species. Following intravenous
injection, ovalbumin-coated erythrocytes were disproportionately targeted by the dendritic
cells capable of indirect antigen specific tolerance. By also incorporating immune-induced
antigens onto the surface of these erythrocytes, the cells promoted targeted depletion of
the CD4 and CD8+ T cells. These findings were further supported with a type I diabetic
mouse model, where antigen-engineered erythrocytes induced clonal depletion of T cells,
and the expression of IFN-γ-positive T cells was significantly reduced over ovalbuminnegative controls and ovalbumin alone.

19

Multiple cell types naturally migrate to the site of inflammation to serve a reparative
function. Drug loaded coatings attached to these naturally-homing cells offer a new
opportunity to target therapies to the inflamed region. However, the coverage of the entire
surface of transporter cells with biomaterials would interfere with the migration and
cellular activities of transporter cells throughout the body. Cellular patches were originally
proposed by Rubner’s group [37, 39] to partially cover the migratory cell with a surface
anchored therapeutic material. In this strategy, polyelectrolyte multilayer (PEM) patches
containing a magnetic nanoparticle payload were adhered onto the lymphocyte surface.
These T cells were nearly 100% viable following patch modification and retained their
migratory capacity with the magnetic PEM patch. This innovative idea of partial surface
modification is appropriate to allow either T cell interactions involved in immunological
responses or drug carrying potential for cell-based drug delivery.
Additional studies in the Mitragotri lab [38] found that PEM-modified multilayer
patches on the surface of mouse macrophages had no adverse effects on cell viability,
migration, or phagocytic activity towards polystyrene spheres. Optimization of PEM patch
size, modulus, and shape enabled prolonged patch attachment on the macrophage surface
without internalization. In vitro controlled loading of FITC-BSA from polymeric patches
supports the feasibility of drug delivery with patch coated cells. Patch-coated and uncoated
monocytes both undergo stimulation-induced differentiation into macrophages. The
targeting of coated monocytes to inflamed skin and lung tissues was supported in mouse
models [65]. Higher accumulation of patch-coated monocytes in inflamed tissue over the
patch alone, illustrated that coated monocytes retained their ability to penetrate across
barriers to target regions of inflammation.
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2.3

Coating designed for cancer therapy
The irregular vessel organization, low oxygen supply, and high interstitial fluid

pressure of large tumors impedes the delivery of drugs into large malignant tissues.
Currently, the majority of tumor-targeting approaches use liposomes, micro- or
nanoparticles, and polymers. However, their insufficient penetration into deep tumor
tissues and rapid clearance limits therapeutic efficacy. The use of tumoritropic cells as
drug carriers is a promising new approach to deeply penetrate tumor tissues and increase
drug efficacy [61].
There are now multiple examples of drug-coated T cells used for tumor-specific
targeting of a therapy [66, 67]. T cells, B cells, and natural killer cells all have some level
of tumoritropic capacity [68-71]. These immune cells migrate across capillaries and blood
vessels to tumor sites by targeting the cytokines released by the cancer microenvironment
[66, 67]. Irvine et al coated T cells with liposomes loaded with cytokines promoting help
T cell differentiation, growth, and endurance at tumor sites [72, 73]. The nanoparticle (NP)
coatings were optimized to minimize any effect on cells’ tumoritropic migration in vitro
and in vivo. Later, this team also studied the cell-based delivery of phosphataseencapsulated lipid nanoparticles to promote T cell expansion through the delivery of Tcell regulating phosphatases [73]. T cells were coated with these therapeutic NPs and used
to treat mouse models of human prostate cancer. Mice treated with coated T cells had
increased T cell expansion, reduced tumor size, and increased animal survival by 60 days
over unmodified T cell groups.
Macrophages are also emerging as a useful tool for cell-mediated penetration into
tumor masses. They effectively carry drug-encapsulated liposomes into tumors for
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simultaneous imaging and therapeutic delivery [74]. After surface modification of
doxorubicin (DOX)-loaded liposomes, these drug-loaded macrophages accumulated at the
tumor site of an A549 xenograft tumor in a mouse model. 24 h after injection,
accumulation of DOX was significantly higher in mice treated with of liposome-DOXloaded macrophages when compared to PBS, macrophage, DOX and liposome-DOXinjected controls. The weekly intravenous injection of coated macrophages also decreased
the tumor size by around 40% when compared to the DOX control group in the same study.
Many stem cell populations also naturally target tumor sites. Neural stem cells
(NSC) are actively studied for the delivery of platinum-based therapies to ovarian tumors
[75]. NSCs are coated with a nonporous silica that encapsulates platinum-based drugs and
has minimal NSC toxicity. These platinum-loaded particles persisted deep inside in solid
tumor masses 24 h following intraperitoneal injection into an ovarian cancer mouse model.
These findings support NSCs as an alternative cell carrier for drug loaded coatings into the
core of tumor masses. Finally, hMSCs are promising for the delivery of nanoparticle
payloads into tumor masses [46]. In one study, NP patches were prepared through the
attachment of NeutrAvidin-coated NPs to partially modify the surface of covalently
biotinylated hMSCs. Coated MSCs targeted HEPG2 tumor spheroids in vitro, and this
approach supports the use of nanoparticle-based coatings for cell-mediated tumor
targeting.
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CHAPTER 3. HYDROGEL PATCHES ON LIVE CELLS THROUGH SURFACE MEDIATED
POLYMERIZATION

3.1

Introduction
Many naturally-occurring cells possess an intrinsic ability to cross biological

barriers that block conventional drug delivery, and these cells offer a possible mode of
active transport across the blood brain barrier or into the core of tumor masses. While
many technologies exist to form complete, nanoparticle loaded coatings on cells, a
complete coating on the cell surface would disrupt the interaction of cells with their
environments. To address this issue, cell surface patches that partially cover cell surfaces
might provide a superior approach for cell mediated therapeutic delivery. In this chapter,
the goal of this study is to establish a simplified approach to produce polymeric patches of
arbitrary shapes on a live cell via surface-mediated photopolymerization. Cell surfaces
were nonspecifically labeled with eosin, and PEGDA coatings were directed to specific
sites using a 530 nm irradiation through a chrome-coated photomask. These coatings may
entrap drug loaded or imaging particles. The nonspecific formation of PEGDA hydrogel
coatings increased with irradiation time, light intensity, and initiating species. 40 mW/cm 2
irradiation for 5 min delivered high-resolution patterns on the surface of A549 cells, and
these cells remained viable for 48 h post-patterning with fluorescent nanoparticle loaded
coatings. This work first demonstrated the feasibility to photo-pattern polymer patches
directly onto the surface of cells. The work presented in this chapter has been published in
the following peer-reviewed journal paper:
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Pei-Jung Wu , Jacob L. Lilly, Roberto Arreaza, and Brad J. Berron*. Hydrogel
Patches

on

Live

Cells

through

Surface-Mediated

Polymerization.

Langmuir, 2017, 33 (27), pp 6778–6784
Reprinted with permission from Hydrogel Patches on Live Cells through SurfaceMediated Polymerization, Copyright 2017, American Chemical Society.

3.2

Background
Targeted delivery seeks to minimize off target effects by localizing the therapeutic

agent to the site of intended action [76, 77]. Much of the prior work focuses on modifying
a therapeutic particle’s surface chemistry, targeting ligands, shape, and size [78-80].
Recently, groups have begun loading a therapeutic cargo on the surface of a cell for a
targeted effect [39, 81]. For example, stem cell-binding silica nanoparticles have been
utilized for delivering doxorubicin to glioma tumor cells [78]. These cell carriers have also
delivered encapsulated drugs through the blood-brain barrier and poorly accessible tumor
tissues [46, 65] . A significant obstacle in these approaches is the adhesion of drugs to the
surface of the transporter cell while not precluding the cell-directed transport throughout
the body or interfering with nutrient transportation through the cell membrane [25, 37]. A
coating that only covers part of a cell’s surface would be capable of drug delivery while
still allowing the cells to interact normally with the body. Swiston and Rubner attached
polyelectrolyte multilayer patches on lymphocytes without altering their survival,
proliferation rate, and normal cell functions [37]. This is the first evidence that cellular
patches can confine a drug cargo to a region of a cell’s surface. Since then, additional
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applications of cell patches have been explored using stem cells for delivery of drug-loaded
polymers to tumor tissue [46] or monocytes to deliver payloads to inflamed tissues [65].
A variety of techniques have been developed to produce drug loaded cellular
patches. The PEM patches made by Rubner et al. were manufactured as pre-patterned films
with a top layer conjugated with a cell binding ligand [37]. A similar concept was applied
by Mitragotri to generate multilayered “backpack” on monocytes composed of poly
(methacrylic acid), poly (vinyl-pyrrolidone), poly (allylamine hydrochloride) and anionic
iron oxide magnetic nanoparticles for delivery to inflamed tissues [38, 65]. The production
of cellular patches through these techniques requires multiple time-consuming steps of
polymer film formation and conjugation. In an alternative approach, Anderson et al. used
sulfosuccinimidyl-6-(biotinamido) hexanoate (sulfo-NHS-LC-biotin) to induce global
biotinylation of cell surface protein on hMSCs, followed by high affinity of biotinylated
cell surface with NeutrAvidin-labelled polystyrene nanoparticles [46]. A limitation of this
technique is that they cannot control the size and shape of the patches, potentially
interfering with robust interactions between the cell and the biological environment.
Here, we establish photolithographic patterning of a polyethylene glycol diacrylate
(PEGDA) hydrogels as a simple technique to produce patches on cell surfaces. The cell
patch approach is based on the eosin mediated photopolymerization of PEGDA, first
demonstrated on cell surfaces by the Hubbell lab [82]. The irradiation of visible light (530
nm) on surface immobilized eosin Y in the presence of TEA initiates PEGDA gel formation
adjacent to the cell surface. While the Hubbell lab loaded high levels of eosin through
nonspecific eosin absorption, our lab has previously synthesized 100 nm thick, nonpatterned PEGDA films on cells with lower eosin loadings. Low levels of eosin
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conjugation (1,600 – 54,000 eosin/µm2) are achieved by contacting a streptavidin-eosin
conjugate with a cell surface specifically labeled with biotinylated antibodies or
nonspecifically labeled with a biotinylated NHS species [24].
In this work, we pattern these coatings on a cell for the first time using standard
photolithographic techniques. We first characterize PEGDA hydrogel formation on a
microarray of biotinylated proteins on glass. The thickness, specificity, and spatial
accuracy of PEGDA pattern formation was evaluated at different irradiation times,
intensities, and mask positions. After pattern gelation trends are established on a glass
substrate, we then apply nanoparticle loaded patches to A549 cells (adenocarcinomic
human alveolar basal epithelial cells). As a potential application, the homing of tumor cells
to pre-existing tumor sites [83, 84] offers an opportunity to direct the transport of drugloaded cells to tumors. A549 cells have been frequently used as an invasive immortalized
cell line for non-small cell lung cancer [85, 86]. The thickness and feature resolution of
PEGDA patches deposited on the surface of A549 cells was characterized, and the effects
of PEGDA pattern formation on cell viability were evaluated. In all, this study investigates
the key parameters governing the formation of cellular patches through surface-mediated
PEGDA photolithography. When compared to existing patch strategies, the simplicity of
this approach decreases the aggregate time and complexity for cellular patch production.

3.3

Experimental section
3.3.1

Materials

Epoxy functionalized slides were obtained from CEL Associates. Bovine serum
albumin

(BSA),

eosin-5-isothiocyanate,
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phosphate-buffered

saline

tablets,

triethanolamine, PEG diacrylate 575, 1-vinyl-2-pyrrolidinone and Whatman chip-clip
were obtained from Sigma Aldrich (St Louis, MO). Poly (ethylene glycol) diacrylate 8000
was purchased from Alfa Aesar. Ethyl alcohol (200 proof) was purchased from Pharmcoaaper. Biotinylated bovine serum albumin, streptavidin, trypsin/EDTA, ethidium
homodimer-1, yellow-green or nile red fluospheres, collagen I rat protein, sulfo-NHS-LCbiotin, 16% paraformaldehyde aqueous solution and DAPI were purchased from Thermo
Fisher scientific. LED lamp with 530 nm wavelength (M530L2-C1) and neutral density
filter (NE260B) were purchased from Thorlabs. Biotin anti-human EpCAM was purchased
from BioLegend. The photomask used for surface patterning was a chrome-coated glass
mask purchased from Louisville Photomask. RPMI-1640 cell culture media was purchased
from Cellgro and supplemented with 10 v/v% fetal bovine serum (FBS, Gibco, Carlsbad,
CA), 100 U/mL Penicillin, 10 mg/mL Streptomycin (Gibco) prior to use.
Adenocarcinomic human alveolar basal epithelial cells (A549) were purchased from
Lonza (Basel, Switzerland). 1X PBS was prepared by dissolving phosphate buffered saline
tablets in ultrapure water according to the manufacturer protocol. Streptavidin-eosin was
prepared as described previously[87]. PBSA was prepared by adding 1 mg/mL bovine
serum albumin to 1X PBS.
3.3.2

Eosin conjugation of biotin-immobilized microarrays

Biotinylated microarrays consisted of an epoxide-coated glass substrate, and serial
dilutions of biotinylated bovine serum albumin (bBSA, from 1000 to 0.105 μg per mL in
PBS) were printed on array surface by GMS Affymetrix 417TM Arrayer. Each
concentration of bBSA was duplicated into two spots. After array printing, the slides were
dried overnight at room temperature and then were stored in a microscope slide storage
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box until use. For each microarray experiment, the bBSA-printed slide was loaded in
Whatman Chip-Clip slide holder, and each Chip-Clip array well was blocked with PBSA
for 45 min to reduce non-specific interaction on unprinted sites. Array wells were then
incubated in streptavidin-eosin (25 μg/mL in PBS) for 30 min.
3.3.3

Culture and eosin photo-initiator conjugation of A549 cells

The A549 cell line was cultured in RPMI-1640 medium containing 10v/v% FBS
and 1% streptomycin/penicillin at 37oC incubator with 5% CO2. Cells were cultured
between 80 and 90 % confluency, and trypsinized prior to use with 0.25% trypsin-EDTA
(Thermo Fisher) in sterile PBS for 5 min. Glass microscope slides (25mm x 75mm) were
sterilized in a conical tube by immersion in 200 proof ethanol overnight before cell culture.
After drying and sterilization, slides placed in a 100 mm petri dish were rinsed with
sterilized PBS twice and incubated with 415 μL collagen I rat protein solution in 20 mL
PBS at room temperature for 1 h. Approximately 5 million cells were cultured on the
collagen-covered slides within a cell culture dish. After cell attachment, cells were cultured
until >90% confluency for polymerization studies.
A549-cultured slides were gradually lowered in temperature prior to incubations on
ice. Specifically, slides in culture dishes were incubated in 25 mL fresh cold medium and
placed at room temperature for 10 min and then on ice for 20 min, washed with ice cold
PBS and then loaded into a Whatman slide holder. Each cell well on Whatman Chip-Clip
was rinsed with 400 μL PBS three times. After rinsing, a freshly prepared biotinylation
solution of 1 mM sulfo-NHS-LC-biotin was added to the cells for 30 min. Biotinylated
cells were rinsed with cold PBS three times and incubated with 35 μg/mL streptavidin-
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eosin in PBS for 30 min. After photoinitiator conjugation, cell slides were rinsed with PBS
three times.
3.3.4

Non-patterned polymerization of PEGDA on biotin-immobilized microarrays
PEGDA monomer was composed of 25 w/v% PEG diacrylate 575, 21 or 210 mM

triethanolamine, and 35 mM vinyl pyrrolidinone. Irradiation conditions were 20, 30, or
40mW/cm2. The thickness of PEGDA hydrogel on microarray system was observed by
Dektak 6M stylus surface profilometer. The estimation of PEGDA hydrogel thickness by
fluorophore was performed by the addition of yellow green fluospheres (2.5 v/v%, Life
Technology) into the PEGDA monomer solution. The fluorescence of yellow green
fluospheres was obtained by Nikon Eclipse Ti-U microscope with filter set of 470/535
excitation /emission. Fluorescence intensity was quantified by image analysis using
ImageJ software.
3.3.5

Photo-lithographic polymerization of PEGDA hydrogel patches on biotinimmobilized microarray or adherent live cells
For PEGDA hydrogel patches formation, bBSA-immobilized epoxy microarray or

biotinylated A549 cell surface provided binding sites for streptavidin-eosin conjugation.
For photolithographic polymerization, the slide (microarray or cell slide) was separated
from the photomask with two 40 μm thick spacers, and this assembly was held together
with binder clips. The photomask features consisted of 10 μm thick chrome stripes
separated by 28 μm spaces. For microarray polymerization, a neutral density filter was
attached under the glass slide to minimize reflection of the light, and the monomer solution
was a solution of 25 w/v% PEG diacrylate 575, 21 or 210mM triethanolamine, 35 mM
vinyl pyrollidinone and 2.5v/v% yellow green Fluospheres in deionized water. For patch
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polymerization on live A549 cells, the monomer solution contained 10 w/v% PEG
diacrylate 8000, 21 mM triethanolamine, 35 mM vinyl pyrollidinone and 2.5 v/v% yellow
green fluospheres in PBS, and the pH was adjusted to 7.4 with the addition of 1.2 molar
hydrochloride, as needed. Monomer solutions were bubbled with ultrapure nitrogen in the
dark for 10 min before photopolymerization. For polymerization, the PEGDA monomer
solution was pipetted into the space between the slide and photomask. The whole
photomask assembly system was purged with nitrogen for 3 min. The photomaskassembled slide was then irradiated under visible-light exposure with peak wavelength of
530 nm with continuous ultra-pure nitrogen purge. The desired light intensity and
irradiation time period was selected as a parameter for polymerization. After irradiation,
microarray slides were gently rinsed with deionized water, blown dry with house air, and
stored in a microscope slide box. Polymerized cell slides were gently removed from the
photomask assembly, re-loaded into Whatman chip-clip, and rinsed with PBS three times.
Images of hydrogel patches were obtained by epi-fluorescence microscopy (Nikon Eclipse
Ti-U).
3.3.6

Statistical analysis for microarray hydrogel polymerization

The fluorescence intensity of nanoparticle-loaded hydrogel patterns was
quantitated through image analysis using the Image J software. For determination of the
hydrogel pattern accuracy, the normalized sum of squared error and mean peak intensity
were calculated by a custom Matlab program. The experimental data of fluorescence
intensity distribution was normalized and were input into a custom Matlab script to fit a
Gaussian function to the fluorescence data. The midpoint of the Gaussian curve was
considered the midpoint of the pattern. The mean peak intensity was determined by the
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mean of the four data points closest to the pattern midpoint. The normalized ideal pattern
is defined as a 10 µm wide step function with a magnitude equal to 1. The normalized
pattern data was determined by scaling the fluorescent intensity data to a maximum of 1.
The normalized sum of the squared error (Normalized SSE) is defined as the squared
difference between normalized pattern data and normalized ideal pattern.
3.3.7

Membrane integrity assay after hydrogel patch polymerization on A549 cells
After polymerization and rinsing, photopatterned cells were incubated in 2 µM

ethidium homodimer (Life Technologies) diluted in 3 v/v% FBS in PBS for 30 min. Single
channel images were obtained by epi-fluorescence microscopy (Nikon Eclipse Ti-U) and
merged by Image J software.
3.3.8

PEGDA hydrogel formation on fixed A549 cells

A549 cells were grown to ~90% confluency on sterilized glass microscopy slides.
Cells were washed 3 times with cold PBS, then fixed with 1% paraformaldehyde for 10
min, then washed 3 times again with cold PBS. Slides were blocked with 1% BSA in PBS
for 40 min. Cells were stained with 10 nM DAPI in PBS for 10 minutes and rinsed 3 times
with PBS. Slides were then immersed in biotin anti-human EpCAM at 1:100 dilution in
PBS+ 1%BSA for 40 minutes. Slides were rinsed 1 time with PBS+ 1%BSA then
immersed in PBS+ 1%BSA with 25 µg/mL SA-EITC for 30 minutes. The slides were then
rinsed 3 times with PBS and clamped to a chromium/glass photomask with a 40 µm spacer.
A monomer precursor solution was injected into the photomask setup which consisted of
420 mM PEG-diacrylate (Mn ~575), 210 mM triethanolamine, 35 mM vinyl
pyrrolidinone, and 0.05 wt% nile red Fluosphere nanoparticles. The entire setup was then
exposed to 10 mW/cm2 green LED light (Thorlabs) for 10 minutes and rinsed 3 times with
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DI water. After drying, the slides were imaged with an inverted epifluorescent microscope
at 20X objective.

3.4

Results and discussion
Cellular patch fabrication typically consists of patterned layer-by-layer coating

fabrication, adhesion onto the cell surface, and release of the assembly from the
substrate.[37, 46] In this study, we provide a unique approach for the formation of a drugloaded polymer patches through direct photopolymerization of a nanoparticle-loaded
polymer depot on the surface of a live cell. We expect the photo-polymerization of
hydrogel cellular patch to have the following attributes: (a) patch fabrication in a
physiologically-compatible environment; (b) direct hydrogel production onto a portion of
cell membrane without multistep coating prefabrication; (c) highly controllable patch
geometry fine-tuned by irradiation conditions and photomask features. To create
geometrically-controlled polymeric film on the cell’s surface, we take advantage of the
high affinity between biotin and streptavidin to localize eosin on the cell surface. Cell
surface biotinylation is attained through labeling surface proteins with sulfo-NHS-biotin,
and the biotinylated cell surface is contacted with streptavidin-eosin to immobilize low
concentrations of eosin on the surface. A photomask with striped chrome features is placed
above adherent A549 cells, and the gap between the cells and the photomask is filled with
a PEGDA monomer solution. The surface-mediated photopolymerization of PEGDA
hydrogel patches proceeds with green light irradiation at a wavelength of 530 nm (Figure
3.1).
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3.4.1

Characterization of PEGDA film polymerization parameters

The fabrication of PEGDA cellular patches requires a careful balance of gelation
in irradiated regions with soluble macromolecular species in dark regions. The surfacemediated photopolymerization of PEGDA is controlled by multiple key parameters: the
wavelength and intensity of light for photoinitiator excitation, irradiation period,
composition of monomer and co-initiator, and the density of photoinitiators on the cell
surface. These parameters alter the rate of polymer gelation on the cell membrane. In
addition to the complex parameters which govern PEGDA film formation, cells have
irregular geometries which limit our capacity to directly measure PEGDA pattern
thickness on cells. To better characterize PEGDA film formation for eventual use on live
cells, we first utilized an epoxy microarray system without a photomask to characterize
how these same parameters dictate PEGDA film formation. Based on these results, we
identify target conditions for cellular patch construction.
Biotinylated bovine serum albumin (bBSA) microarrays were prepared with serial
biotin concentrations from 0 to 1000 μg/mL bBSA, where these surfaces were made to
represent the possible biotin concentrations on our target cell surfaces [24]. These
microarray surfaces were treated with precursor solution (25 w/v% PEGDA575, 21 or 210
mM TEA, 35 mM VP and 2.5 w/v% yellow-green nanoparticles in deionized water), and
exposed to green light (530 nm) under different irradiation conditions (20, 30, and 40
mW/cm2 for 2.5, 5, and 10 min). The profilometric thickness of PEGDA film generated
based on bBSA concentration gradient was described in Figure 3.2 A With different
irradiation conditions, PEGDA hydrogels were thickest (250 ± 8 nm) under 10 min,
40mW/cm2 irradiation using 210 mM TEA (Figure 3.2 B). With the same TEA
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concentration and irradiation time, lower irradiation intensity (30mW/cm 2 and
20mW/cm2) produced lower peak thickness (182 ± 4 and 177 ± 4 nm, respectively).
Despite the similar peak thickness at high bBSA, 20mW/cm2 irradiation had consistently
lower hydrogel thickness with lower bBSA concentration. Furthermore, under 21 mM
TEA, same irradiation conditions produced lower hydrogel compared to 210 mM TEA
(Figure 3.2 C). Taken together, these results supported that the thickness of the polymer
are predictably controlled by all controllable parameters of the initiation system: the
density of eosin conjugation, the irradiation energy, and the amine coinitiator
concentration [50, 52, 53].
3.4.2

Fluorophore-labeled PEGDA for thickness estimation

For the measurement of PEGDA photopatterned coatings, our profilometer lacks
adequate resolution for PEGDA film features that are less than 1 μm wide because of stylus
tip radius is ~12 μm. To overcome this limitation, we correlated the fluorescence of
embedded nanoparticles to the thickness of a PEGDA films on large features [24], and we
used this correlation to determine submicron feature geometries by epifluorescent
microscopy. We included 2.5 v/v% of yellow-green nanoparticles to become
nonspecifically embedded into the hydrogel during polymerization. Fluorescence was
highly proportional to the actual PEGDA film thickness from 20 to 150 nm (Figure 3.2 B).
This is consistent with our previous report which used fluorescent intensity to estimate of
hydrogel thickness [24]. Furthermore, the fluorescence of yellow green was sufficient to
detect polymer thickness below 50 nm, supporting the feasibility of quantifying PEGDA
pattern height over the relevant thickness scales for surface mediate polymerization of
PEGDA coatings.
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3.4.3

Parameters governing the specificity of gelation in irradiated and nonirradiated regions

To better describe the relationship between the irradiation parameters and localized
gelation via surface mediated polymerization, a chrome photomask was used to restrict the
irradiation to 10 µm stripes on microarrays of biotinylated surfaces (1000 μg/mL). Figure
3.3 schematically describes the photomask system, and a photograph of the system is
provided as Figure A.3. The spacers separating the photomask from the microarray were
40 μm thick for all data shown, while preliminary studies with thicker spacers had lower
feature resolution (60, 80 and 100 μm, Figure 3.4). Fluorescence microscopy was used to
observe the spatial distribution of the fluorescence of yellow-green NPs labeled hydrogel
patches in a 1 mg/mL bBSA printed microarray spot. Both brightfield and fluorescence
(ex/em 470/535 nm) microscopy confirm that 10 μm green striped hydrogel patterns were
confined to regions within the photoinitiator-bound array spots (Figure 3.3). The
localization of polymer stripes to circular regions confirmed the polymerization was driven
by specific binding of eosin to the microarray spots.
The intensity of fluorescence in both irradiated and non-irradiated regions of the
array spot was analyzed by imageJ. The intensity was then converted to an estimated
thickness based on the fluorescence-thickness relationship curve described in Figure 3.2
C. The thickness at non-irradiated regions was consistently < 5 nm and was not dependent
on light intensity and irradiation period (Figure 3.5). To reduce the light reflection at the
back side of the glass substrate, a neutral density filter was applied to decrease polymer
formation in non-irradiated regions of array spots (Figure 3.6).
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For the irradiated region of the array spot and a 2.5 min irradiation period, there
was extremely low thickness (<5 nm) showing that no observable polymerization occurred
for intensities up to and including 40 mW/cm2 (Figure 3.7B). For the irradiated regions
using light intensities of 30 and 40 mW/cm2 with times of 5 or 10 min, the thickness was
considerably higher (>30 nm). In contrast, when light intensity was lowered to 20
mW/cm2, almost no polymer film was generated. The polymer thickness increased with
both light intensity and irradiation time, and these trends are consistent with unpatterned
coatings (Figure 3.2B). In all, there is a strong relationship between coating thickness and
irradiation intensity and time within the irradiated area (Figure 3.7B), while the nonirradiated area is largely independent (Figure 3.5). However, there was lower polymer
formation under neutral density filter compared to polymerization without the neutral
density filter (Figure 3.2 and Figure 3.7). The lower thickness is consistent with a lower
contribution of reflected light to the irradiation regions, creating a compromise between
improved feature sharpness and overall polymer thickness. In all, these trends support a
parameter space for successful pattern formation: 5-10 min irradiation at 30-40 mW/cm 2.
3.4.4

Analysis of coating feature edge sharpness

To quantify the accuracy of the pattern transferred from the photomask to the
polymer patch, a normalized sum of square error (SSE) was calculated between the
experimental topography and an ideal step pattern (Figure 3.7A and 3.7B). The SSE of the
patterned PEGDA film increased with both irradiation intensity and duration (Figure
3.7C). In general, the polymer features were larger than the ideal dimensions, and this
excess polymerization is attributed to the diffusion of oligomers and actively polymerizing
chains into adjacent non-irradiated areas. Our data shows 40 mW/cm2, 5 min of irradiation
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generated the PEGDA film with over 50 nm thickness, which is sufficient to load
nanoparticles [54], but also with modest SSE compared to 40 mW/cm 2, 10 min or 30
mW/cm2, 10 min. In all, high irradiation intensities coupled with low exposure times are
supportive of thick polymer coatings and high feature accuracy.
3.4.5

Parameters governing PEGDA pattern formation and viability on A549 cells
To generate PEGDA film on cell surface, A549 cell surfaces were first biotinylated

with sulfo-NHS-biotin. Then, slides with biotinylated A549 cells were inserted into the
same apparatus described in Figure 3.3A. To minimize monomer toxicity, we used
PEGDA 8000 as the monomer unit for cell surface PEGDA hydrogel photopatterning.
PEGDA monomers with higher molecular weights have shown to generate less stress and
more biocompatible [88]. A lower concentration of TEA (21 mM) was used for cell surface
PEGDA hydrogel formation because higher concentrations (210 mM) are toxic to the cells
[25]. PEGDA hydrogel are successfully patterned onto A549 cells with monomer solution
25 and 15 w/v% PEGDA 8000 polymerized under 40 mW/cm2 for 5 min, but these
conditions also correlated with significant amount of cell death in the irradiated region
where PEGDA polymer was generated (Figure 3.8). 10 w/v% of PEGDA 8000 was
sufficient to polymerize PEGDA patterns as evidenced by fluorescence signal of yellow
green nanoparticle loading, but with much lower cell death rate (Figure 3.9). Most
importantly, A549 cell survival rate was not affected after 48 hours of incubation followed
by PEGDA patch generation. As such, photopolymerization is capable of generating
partial polymer coatings onto live cells in a rapid manner. Furthermore, the shape of the
patch is modified through the selection of an appropriate photomask. Stripes of 10, 20, and
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40 µm pitch and circles of 5 and 20 µm are easily achieved on cellular substrates (Figure
3.10).

3.5

Conclusions
This study provides a feasible approach to control the shape of PEGDA hydrogel

films on live cells. Also, in contrast to existing methods, our approach avoids multiple,
time-consuming fabrication processes required in advance of the patch deposition. Most
importantly, PEGDA patches formed through photomask-governed photopolymerization
does not impact the survival of cells, suggesting the potential use of these coatings as
biologically-guided, drug delivery vehicles. Further investigation is justified to determine
the effects of these patches on cell biological functions and to conjugate therapeutic
nanoparticles into these cell patch matrices for therapeutic applications.
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Figure 3-1. Schematic description of A549 cell surface patch photopolymerization.
(A) Cells are cultured on the collagen-coated slide, and cell surface proteins are targeted
and biotinylated by sulfo-NHS-biotin. (B) Cell surface biotin is conjugated with the
streptavidin− eosin conjugate. (C) The PEGDA monomer solution is injected into the gap
between the photomask and cell slides. Formation of PEGDA hydrogel patches is
photopolymerized in the presence of the photomask, which allows only light passing
through the restricted irradiation region to trigger photopolymerization. TEA denotes
triethanolamine, and VP denotes 1-vinyl 2-pyrrolidinone.
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Figure 3-2. Epoxy microarray system for characterizing PEGDA hydrogel formation
via photopolymerization. (A) Arrangement of the bBSA microarray on an epoxy
microscope slide. Twelve concentrations of bBSA were printed from 1000 to 0 μg/mL, and
each concentration has two replicates. (B) Relationship between the log bBSA
concentration and the PEGDA 575 hydrogel thickness under various light intensities, TEA
concentrations, and irradiation times. Data are given as means ± the standard error of the
mean (SEM). (C) Relationship between fluorescence and polymer film thickness. Data are
given as means ± SEM. The fluorescence was contributed by yellow-green nanoparticle
loading in a PEGDA 575 hydrogel.
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Figure 3-3. Photopatterned PEGDA hydrogels in a microarray format. (A) Schematic
diagram of the experimental setup of the photomask covering a biotinylated BSA-printed
epoxy microarray. (B) Bright field image of patterned PEGDA hydrogels (left) and
epifluorescent image of patterned PEGDA hydrogels stained with green fluorescent
particles (right). The photomask had 10 μm wide irradiated regions. The spacer thickness
is 40 μm. The scale bar is 100 μm.
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Figure 3-4. PEGDA 575 stripe patch polymerized with different thickness of spacers.
The spacers used for photomask setup are 40, 60, 80 and 100 μm, respectively. Scale bar
is 100 μm.
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Figure 3-5. Relationship between fluorescence intensity of PEGDA 575 pattern and
irradiation period. For fluorescence at irradiated regions, close diamond: 40 mW/cm2;
close square: 30 mW/cm2, and close circle: 20 mW/cm2) and irradiation period (2.5, 5 and
10 min). For fluorescence at non-irradiated regions, opened diamond: 40 mW/cm 2; opened
square: 30 mW/cm2, and opened circle: 20 mW/cm2) and irradiation period (2.5, 5 and 10
min).
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Figure 3-6. PEGDA 575 photopatterned patches on microarray spots with and
without the use of neutral density filter. Scale bar is 100 μm.
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Figure 3-7. Analysis of PEGDA hydrogel formation rate and accuracy. (A) Schematic
graph from Matlab analysis of the sum of the square error for PEGDA of photopatterning.
The dark blue dots are input data of normalized pattern fluorescence. The Gaussian fit (red
curve) was used to fit the data to obtain the midpoint of experimental results. Four data
points near the center were averaged to determine the normalized fluorescence value of the
ideal pattern profile. SSE was calculated by the square difference between experimental
data and ideal pattern value. The light blue line presents the value of SSE for each data
point. (B) Relationship of PEGDA 575 gel pattern thickness and irradiation period under
different light intensities. The nanoparticle-loaded PEGDA hydrogel was polymerized
under various light intensities [(◆) 40, (■) 30, and (●) 20 mW/cm2] for various irradiation
periods (2.5, 5, and 10 min). The fluorescence of the hydrogel pattern was analyzed by
imageJ and then converted to polymer thickness according to the relationship between
fluorescence and polymer film height. (C) Relationship between normalized SSE and
irradiation period under different light intensities. The normalized SSE of the hydrogel
pattern was analyzed by Matlab: () 40, (···) 30, and (---) 20 mW/cm2.
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Figure 3-8. Cell viability after hydrogel patch formation with 15 and 25 w/v%
PEGDA8000 loading. After polymerization, cells were immediately stained with ethidium
homodimer. The red fluorescence showed that large number of cells at irradiated region
were dying with higher concentration of PEGDA 8000 monomer.
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Figure 3-9. Cell membrane permeability following hydrogel patch formation. The
PEGDA 8000 hydrogel patches were polymerized under 40 mW/cm2 for 5 min. The TEA
concentration was 21 mM. After polymerization, cells were (A) stained with ethidium
homodimer immediately or incubated in medium at 37 °C with 5% CO 2 for (B) 12, (C) 24,
or (D) 48 h. The green fluorescence resulted from the yellow-green loaded hydrogel
patches on the surface of adherent A549 cells. The red fluorescence indicates the
complexation of the ethidium homodimer with cellular DNA in the nucleus of a
compromised cell. The scale bar is 100 μm.
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Figure 3-10. Hydrogel patch formation with different photomask geometries. Under
fixed cell system, nuclei were stained using DAPI, and nile red fluorosphere-loaded
PEGDA hydrogels were patterned based on different features of photomask: (A) stripe
shape with width of 10, 20 and 40 µm; scale bar is 100µm; (B) circular shape with
diameters of 5 and 20µm; scale bar is 20µm.
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CHAPTER 4. BIO-INTERACTIVE COATING FOR MSC-BASED MYOCARDIAL INFARCTION
THERAPY
4.1

Introduction
Myocardial infarction (MI) is a global mortal and morbid disorder that can lead to

a series of cardiac abnormalities, such as reduced left ventricular (LV) ejection fraction,
abnormal LV volume, cardiomyopathy and scarring formation, or, even worse, other acute
systemic diseases, such as kidney failure, stroke, or angina. MI occurs when blood clots
acutely block the coronary artery, resulting in the lack of oxygen and nutrient supply to
local tissues. The decreased oxygen level chronically present in the cardiac environment
seriously endangers functional myocardium, negatively affecting their viability and
contractibility for preserving regular cardiac activities. At present, long-term cardiac
treatment has only been through passive strategies by either controlling multiple cardiac
risk factors such as the level of blood glucose, blood pressure and cholesterol to regulate
cardiac functions, or offering some anti-thrombotic and anti-platelet drugs to prevent blood
clots. Although these therapeutic methodologies can moderately relieve the burden on the
heart, they still cannot repair damaged myocardial functions, reduce scarring formation or
rejuvenate necrotic cardiomyocytes. Therefore, the use of regenerative stem cells has led
to new generation of regenerative therapy, especially for therapeutic homing to damaged
tissues.
While stem cells allow specialized cell differentiation, local adherence of these
therapeutic cells to a targeted tissue location after transplantation is highly limited due to
the absence of homing ligand on cell surfaces. Thus, tailoring stem cell membranes with
specific targeting reagents can provide functional characteristics which actively direct
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modified cells to the targeted destination. This chapter will first discuss therapeutic roles
of MSCs through either immunomodulation or differentiation methods in MI therapy.
Secondly, current surface coating techniques with targeting materials such as antibody or
ligands will be discussed to localize inflamed or infarcted tissues for MI treatment,
providing a basic understanding of material selection and targeting parameters to assist
tissue targeting efficacy. At last, the chapter will also focus on present cell surface coating
techniques that simultaneously satisfied the need of disease targeting effects and the
retention of intrinsic therapeutic functions on treated cells.

4.2

Stem cell-based therapy for myocardial infarction
Occlusion to cardiac blood flow creates acute ischemia and a persistent hypoxic

environment. Based on the cardiomyocyte’s inability to self-regenerate and repair, cardiac
ischemia leads to severe necrosis and a permanent decrease in contractility. While various
reperfusion efforts showed reduced infarct size and modestly improved vascular
endothelial functions [89], there is no effective clinical methodology to compensate the
irreversible loss of cardiomyocytes after MI. As a result, therapies which protect or
regenerate tissues post MI are of the utmost urgency.
Several stem cell therapies are promising for the treatment ischemic heart diseases
due to their capacity for differentiation, regeneration, and modulation of inflammation.
Several types of stem cells, such as hematopoietic stem cells [90], skeletal muscle stem
cells [91, 92], bone marrow cells [93, 94], cardiac stem cells [95]and MSCs [96], have
been broadly utilized in cardiovascular therapy. The infusion of progenitor cells, bone
marrow-derived stem cells and MSCs to damaged tissues have been proposed to support
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normal biological functions of the heart following an ischemic event. Moreover, the
delivery of therapeutic MSCs effectively improve the contractility and functionality of
cardiac muscles, encouraging future use of MSCs for protection of heart function.

4.3

Mechanism of MSC-based cardiac protection
4.3.1

MSC-induced Immunosuppression effects

Accumulating evidence supports the use of MSC-based cardiac therapies in an
immunosuppressive role to protect health myocardial tissue. The introduction of MSCs in
buffer to an infarcted heart reduces the scar size and increases cardiovascular function over
the introduction of buffers alone [97, 98]. Excessive immune responses cause persistent
damage to heart tissues. The biological functions and actions of activated immune cells
are closely correlated to MSC interactions (Figure 4.1) [99, 100]. Most significantly, MSCmacrophage communication drives macrophage polarization and function. The
macrophage secretion of anti-inflammatory cytokine IL-10 is modulated by MSCs to drive
a phenotypic change of macrophages toward an anti-inflammatory state. This presence of
anti-inflammatory macrophages is critical, as the addition of MSCs with the complete
depletion of the macrophage population significantly increased cardiac adverse
remodeling and mortality in vivo [100]. Taken together, the introduction of MSCs acts as
an immunosuppressive mediator to defense overresponsive inflammation [101].
MSCs modulate many species in the post-MI environment to modulate
inflammation beyond interaction with macrophages. IFN-γ and other proinflammatory
cytokines are secreted from activated T cells, and in combination with TNF-α, IL1-α and
IL-1β, these factors drive MSC-associated immunosuppressive functions [101-103].
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Following a T cell-triggered phenotype shift, MSCs secrete multiple biological molecules
that directly participate in immune cell pathways, including IDO enzyme, HLA-G5,
iNOS/NO, prostaglandin E2 (PGE2), HGF or IL-6, to alter the state of immune cells,
including cytotoxic T cells, T regulatory cells, natural killer cells, dendritic cells, monocyte
or macrophage [101]. Immunocyte activities are also suppressed by MSC through direct
and indirect pathways

[104-106]. Furthermore, the proliferation of CD4 and CD8 T cells

can be inhibited by nitric oxide [104] or HLA-G5 [107] production, cellular division and
IL-2 generation from T cells can be delayed by PGE2-stimulated pathway [108], and
intracellular apoptosis signaling can be processed by secreted IL-6 [109].
4.3.2

Mechanism of MSC differentiation into cardiac-related cell lineages

The multipotency of MSC also offers the potential for differentiation into multiple
cardiac cell lineages. The elevated expression of VEGF and FGF in an infarct environment
supports MSC reprogramming into several types of vascular-phenotypic cells, including
endothelial cells (EC) and smooth muscle cells, which are essential and fundamental
components to structurally and physiologically support vasculature reconstruction [110114]. In heart, the abundance of laminin proteins in extracellular matrix could induce
FOX2 upregulated pathway that promotes the EC marker expression and EC-like tubular
network formation on MSCs [115].
MSCs are also inducible into a cardiomyocyte lineage. Specific paracrine growth
signals will drive MSCs towards a cardiomyocyte-like state [114, 116]. IGF-1 pushes the
MSC to increase myocardial marker expression through the PI3k/Akt pathway.
Alternatively, the cardiomyocyte differentiation efficacy of engrafted MSCs can be
effectively enhanced by reacting bFGF in ischemic environment [116]. Other than growth
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factors, the exposure of chemical modifier 5-Azacytidine stimulates MSCs’
cardiomyogenesis through extracellular signal related kinases (ERK) activation pathway
[117] from the evidence of increased cell beating actions and ventricular morphology shift
[118].
4.3.3

Other protective mechanisms of MSCs

Several other beneficial mechanisms of action have been proposed to explain the
therapeutic effects of MSCs in the post-MI myocardium. It has been proposed that MSCs
inhibit the activties of proteolytic cathepsins that degrade extracellular matrix (ECM)
during heart remodeling [99, 100]. Additionally, MSCs mediate blood coagulation and
further clotting-associated heart damage [119-121] through the upregulation of urokinase
plasminogen activator and plasmin activators to block thrombus formation [120]. Finally,
MSCs excrete fibrinolytic enzymes to inhibit scar formation by cleaving the fibrin matrix
formed during cardiac remodeling state [121].
4.3.4

The role of endothelium as a pathological target in MI

Endothelium is a defensive interface which plays an essential role in regulating
vascular functions, such as clot reduction, oxidative species production and inflammation
stimulation. This protective endothelial cell-aligned layer also serves as a significant
pathological target of various diseases, such us MI, cancers or other inflammatory-related
diseases, when multiple biological events simultaneously occurs near vessel regions,
including recruitment of immune cells, diffusion of excess oxidative stresses and induction
of thrombosis triggered by serious damages near injured tissues [122].Typically, healthy
endothelial cells are prominent hallmarks to regulate cardiac metabolism, contractility and
maintain basic cardiac functions. In MI, persistent ischemic injury in infarct sites,
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however, occurs with severe necrosis, apoptosis and metabolic dysfunction of cardiac
cells, initiating destructive degradation processes of intracellular matrix. Continuous
stimulation and generation of degraded cellular contents as well as reactive oxidative stress
to adjacent extracellular components induces upregulation of pro-inflammatory
chemokines that can significantly change endothelium phenotypes. TNF-α is a proinflammatory protein that is highly upregulated after acute ischemia. As TNF-α is released
into inflamed heart, the binding interaction between endothelial surface receptor TNFR
and its ligand cytokine TNF-α results in a series of upregulated protein transcription of cell
adhesion molecules (CAMs) on endothelial surfaces by triggering NF-ĸB-based signaling
pathway [123, 124]. This inflammatory mediator-induced phenotypic alterations on
endothelial cells is so called “endothelium activation”.
With elevated biological marker presence on cell surfaces following MI-induced
inflammation, this activated, antigen-overexpressed endothelium layer can be recognized
as a highly adhesive interface to attract circulating immunocytes, such as leukocyte,
monocyte and neutrophil. When inflammation takes place at a site of injury, inflammatory
cytokines release recruiting signals for leukocyte surface activation. The cause of activated
leukocyte extravasation is the conjunction of sequential biomechanical processes near
vascular endothelium, including slow radial motion (rolling), ligand-receptor capture,
tethering, firm adhesion and then transendothelial migration (Figure 4.2). The surface
receptor B2-integrins, LFA-1 and Mac-1, highly expressed on activated leukocytes have
strong affinity toward corresponding ligands such as selectin glycoproteins, ICAM1 or
VCAM1 on antigen-elevated endothelial alignment [125, 126]. Once the contact between
leukocyte surface integrin and endothelial surface CAMs occurs, this ligand-receptor
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affinity promotes the deceleration of leukocyte flowing speed (rolling) through the
interface of inflamed microvasculature and then lead to leukocyte adhesion, allowing
leukocyte penetration through the gap between adjacent endothelial cells for further
leukocyte infiltration into deep tissue area. By understanding cell recruitment behavior
through inflammation targeting, we will coat MSC membrane with specific targeting
materials to assist MSC migration to ischemic heart by mimicking leukocyte adhesion on
inflamed endothelium.

4.4

Surface coating techniques for targeting endothelium
Vessel interfaces where endothelium locates are always bearing shear stress from

peripherical blood, making endothelial cells difficult to be targeted. Thus, several cell
surface markers of endothelium containing selectins and CAMs were revealed as primary
targeting sites to deliver drugs, like antioxidant and anti-thrombotic molecules, to
endothelium layer [127]. To successfully transport drug carriers to targeted tissues, a
variety of biomaterials has been surface-coated with specific ligands or antibodies. Early
research from Steinberg’s lab first established the delivery of immunoconjugate beads for
cell targeting. The coating of lysosomal-targeted antibody on the surface of polystyrene
Latex spheres was used to examine the lysosomal-mediated actin differentiation activities
after macrophage phagocytosis [128]. This IgG-coated bead technique was further
developed for the surface loading of endothelium-targeted antibodies to target CAMoverexpressed or activated endothelial cells.
Multiple studies using anti-ICAM1 coating for endothelium targeting has been
widely applied in different disease treatment. For example, the anti-ICAM1 coated
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nanobeads with a payload of lysosomal enzyme, which can metabolize excess lysosomal
stored in tissues, has been utilized for enzyme replacement therapy of Niemann-Pick
disease [129, 130]. Compared with non-anti-ICAM1-coated group, significantly decreased
lysosomal accumulation was observed in endothelial cytoplasm [130] or microvasculature
[129]after the delivery of anti-ICAM-coated drug vehicles without tissue injury. Another
example is to coat ICAM1 antibody on the surface of catalyze-loaded latex microbeads to
protect endothelial cells from H2O2-induced oxidative stress. With the coating of targeting
antibody and loading of H2O2-degradable enzyme, anti- endothelial cells were successfully
targeted and able to survive under H2O2 shock after the internalization of catalyze-loaded
beads [131].
While multiple studies broadly displayed the use of anti-endothelium beads in
different disease targeting purposes, key parameters that are responsible for endothelium
binding has been deeply explored to understand optimized coating design for adhesion
efficacy improvement. Importantly, Eckmann et al. has indicated that the density of
surface-coated ICAM1 antibody on polystyrene beads is highly dependent on material
association with ICAM1-expressed endothelium under shear flow, providing the facts that
antigen-targeted adhesion property can be precisely tuned by surface coating
characterization [132].

4.5

Cell surface coating for targeting endothelium
Stem cells are known to lack homing ligands that target specific cell surface

markers present on inflamed tissues. Engineering cell membranes with tissue-targeting
molecules is a promising strategy to assist the orientation of ligand-deficient stem cells
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toward the inflamed endothelium. For instance, by modifying cell surface with selectintargeted ligand sLex, Karp et al. successfully mediate leucocyte-mimicking MSC rolling
on in vitro selectin-localized surfaces [133] and in vivo inflammation-promoted tissues
[45]. They demonstrated two different coating techniques to associate sLex ligands with
MSCs. The first cell surface coating strategy is achieved by using biotin-streptavidin
affinity to conjugate biotinylated sLex onto streptavidin/lipid-bound cells. The second
method demonstrated the anchorage of nanosized polymer- sLe x chain onto MSC surfaces.
For both SLex-coating studies, reduced rolling velocities of sLex-coated cells on P-selectinmodified surfaces were observed under a flow chamber assay, designed to simulate cell
movement behavior through inner blood vessel wall [45, 133]. Compared to the uncoated
cells, in vivo nanosized polymer-sLex-coated MSC rolling was also discovered under a
dynamic real time microscopy and around 35-fold increased sLe x-coated cells were found
in LPS-induced inflamed ear [45]. Instead of applying a coating of natural cell surface
ligand, Kong’s group used cell coating technique to apply VCAM1-associated material on
MSC surfaces. Nanoscale coating of synthetic VCAM-binding peptide (VBP) was
hydrophobically embedded on MSC membranes to target activated endothelium and
vasculature. This group used surface plasmon resonance to detect the adhesion efficacy of
VBP-coated cells or VBP peptides on VCAM-expressed endothelium and VCAM1containing surfaces. The hyper branch-structured polyglycerol chain that contains VBP
was proved to have increased association rate constant and lower dissociation rate constant
than only polyglycerol-coated cells, indicating the implication of surface-coated VBP is a
key element to cause cell rolling in lower speed and enhance cell attachment on an
endothelial layer [134].
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The other way to specifically bind activated endothelium is the MSC surface
coating with artificial antibodies that have high affinity with endothelial surface CAMs
(Figure 4.3). Palmitated protein-G-(PPG)-associated lipid was hydrophobically
intercalated on MSCs by In Kap Ko et al., allowing the capture of IgG-type antibodies on
cell membranes by PPG-guided absorption. To determine if cell surface coating of PPGanti-ICAM1 enhances MSC retention, a physiological flow assay showed the significant
increase of MSC resistance to shear stress on anti-ICAM1-coated groups [135]. In the
same lab, they also established the first animal study to deliver antibody-modified MSCs
for in vivo treatment of inflammatory bowel disease (IBD) in which cell surface addressin
is highly expressed on intestinal endothelial layers as a targeting aim. The goal of this
study is to examine MSC immunosuppressive effects on inflamed colon tissues and
mesenteric lymph nodes to inhibit immunoactivities following the targeted delivery of
antibody-engineered MSCs. It was proved that the increased retention of PPG-MSCs,
incorporated either VCAM1 or addressin antibody, is able to delay spleenocyte
proliferation, induce the presence of T regulatory cells, and enhance the survival rate of
IBD-induced mice [136]. While antibody-PPG incorporation exhibited great endothelium
targeting efficacy in both in vitro and in vivo studies, this protein-G coating technique that
only has ability to absorb immunoglobin highly restricts the selection of cell-targeting
materials that can be incorporated on the cell surfaces.

4.6

Cell surface coatings for targeting myocardial infarcts
In addition to inflammation targeting, cell surface coating through other targeting

aims are also employed in cardiovascular diseases. For instance, magnetic nanoparticles
58

have been widely used in various bioimaging and biomedical applications because of their
responsive properties under magnetic stimuli. Cheng’s group deposited an FDA-approved
FHP (Feraheme, heparin and protamine) magnetic nanocomposite for cardiosphere-

derived stem cell (CDC) membrane coating to provide cell targeting and imaging
potentials [137]. The study showed this cell surface deposition with ferromagnetic
particles had no change in several cellular activities, such as differentiation, proliferation,
migration, and no oxidative stress was generated in the FHP-coated CDCs. Besides, this
iron-contained cell coating could be magnetically regulated in vivo to effectively examine
the mobility of coated cells under an external magnetic field and caused increased retention
at the infarcted heart region only with coated cell group. Although FHP cell coating on
CDC cells was loaded through natural cellular uptake, this strategy might accumulate in
non-infarcted region and affect long-term intracellular activities due to the lack of cell
ability to metabolize this uptake materials in the cytoplasm. Additionally, SPIONs
(superparamagnetic iron oxide nanoparticles) are also a popular nanomedicine applied on
stem cells because of their imaging, tracking and targeting potentials for MRI or magneticbased diagnostic assays. However, significant obstacles exist due to their poor metabolism
and body clearance, unfavorable release to extracellular environment and long-term
oxidative stress production [138].
Following an ischemic shock, a variety of chemokines were recruited near oxygendeficient infarcts and play an important role in regulating anti-apoptosis and angiogenesis
effects [139]. Importantly, the low oxygen level triggers the production of HIF-1α,
resulting in the upregulation of a stem cell recruited chemokine, SDF-1 (stromal cellderived factor-1) in the infarct site [140]. Thus, to enhance stem cell migration and
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recruitment to myocardium infarcts, the presence of SDF-1 under hypoxia condition has
been considered as a significant target by using the interaction between SDF-1 and its
receptor CXCR4. The cell modification work from Bull’s lab demonstrated the CXCR4conjugated lipid coating on MSC membranes significantly enhance cell migration toward
SDF-1 containing environment [12]. The migration feature of CXCR4-coated cells is
highly dependent on the dose of SDF-1. This ligand-incorporation work indicated MSC
recruitment potentials to hypoxia myocadiac regions by cell membrane engineering.
Cardiomyocyte necrosis accompanying with myofilament remodeling causes
substantial release and degradation of proteins, vasculature fragment, proteinases and
enzymes. Elevated breakdown of damaged cardiac molecules has been clinically identified
as one of important diagnostic indicators of cardiac dysfunction following MI. During
ischemia, the release of myosin light chain (MLC), a cleavage form of contractile cardiac
myosin, can be stimulated by MMP-2-guided proteolysis, leading to huge loss of
contractility and mobility of cardiac muscles [141, 142]. Importantly, it has been clinically
found that MLC quickly accumulated and reached peak concentration near injured heart
several days post MI and is closely related to the size of infarct scarring [143], suggesting
this ventricular myosin fragment can be a significant targeting marker of MI. Similar to
previously mentioned antibody incorporation for endothelium targeting, antibody coating
on stem cells was also utilized to target MLC in damaged heart. A bifunctional antibody
that has dual targeting abilities was designed by Lee RJ et al. to act on both transporting
therapeutic cells and targeted cells. To create an antibody hybrid, two distinct antibodies
(anti-CD45 and anti-MLC) were modified by amine-reacted Traut’s reagent and sulpho
SMCC, respectively, to present sulfhydryl and maleimide groups on each IgG chain for
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dual antibody conjugation [144, 145]. The delivery of bispecific antibody-coated
hematopoietic stem cells (HSCs) was used to target myosin-exposed cardiac cells, showing
improved ventricular biofunctions with the increased HSC retention 5 weeks post MI
[144]. The group using biospecific antibody coating strategy also proved therapeutic
effects in a Langendorff-perfusion mice heart model. The in vivo intravenous
administration suggested the ability of antibody-coating to restore biological functions of
cardiac vasculature and to reduce myocardial degradation and fibrosis formation [145].
Unfortunately, this anti-MLC coating methodology might mislead surface-coated MSC
toward undesired destination, since the increased release of myosin fragment into
circulating blood serum several days following heart failure [143] makes this pathological
cardiac maker difficult to be specifically targeted only in the ischemic region. Although
the incorporation of bispecific antibody has high specificity for dual cell targeting, the
efficacy of cell surface coating by antibody-antigen recognition can be limited. The
insufficient and restricted marker density and diversity of cell surface antigen expression
on different cell types make antibody-based coatings less competitive and less adjustable
than other cell surface modification techniques.
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Figure 4-1. Immunomodulation strategies of mesenchymal stem cells. Reprinted with
permission from [146], Copyright 2016.
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170601/?report=reader)
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Figure 4-2. The mechanism of leukocyte transendothelial migration. Reprinted with
permission from [147], Copyright 2015, with permission from Springer Nature.
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Figure 4-3. MSC surface coating of ICAM1 antibody for endothelium targeting.
Reprinted with permission from [135], Copyright 2009, with permission from Elsevier.
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CHAPTER 5. ICAM1-ADHESIVE MSC FOR ENHANCED CELL RETENTION VIA
INTRAMYOCARDIAL DELIVERY

5.1

Introduction
Intramyocardial delivery is a direct route for placing MSCs into an inflamed heart

to regulate the local inflammation response. The retention of MSCs at the injection site is
severely limited by the fluid flows that rapidly wash cells away and minimize their
capacity to modulate cardiac inflammation. To prevent this loss of MSCs and their
function, this chapter will focus on the development of an anti-ICAM1 coatings on the
plasma membrane of MSCs to enhance their adhesion to their inflamed environment.
Covalently biotinylated MSCs were tethered to biotinylated anti-ICAM1 through an
intermediate deposition of streptavidin layer with unsaturated biotin binding domains.
MSC surfaces were modified with ~7,000 biotin/µm2 and ~23 antibodies/ µm2. The
intramyocardial injection of antibody-coated MSCs offered a 3-fold increase of cell
retention in the heart over the injection of uncoated MSCs. The mechanism of adhesion
was supported through analysis of MSC adhesion to activated HUVECs and surfaces of
purified ICAM1 glass under microfluidic shear flow.

5.2

Background
MIs are severe cardiovascular events where the occlusion of the blood supply

damages local tissues. Without access to oxygen and essential nutrients, cells within the
infarct zone become necrotic and release waves of cytokines driving local inflammation
to recruit additional inflammatory cells and alter the phenotype of local cells. The spike in
inflammation drives the spread of damage to tissue outside the initial infarct site, and this
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wave of inflammation-driven damage continues to spread out into healthy heart tissue for
weeks following the initial occlusion. As a result, MI-associated damage is dramatically
worsened by unchecked inflammation following the initial injury.
MSCs are potent modulators of inflammation and have been effectively utilized in
vivo to promote immunomodulatory effects of immunocytes, including CD8 T cell, T
lymphocyte, natural killer cells, dendritic cells and macrophage [104, 107-109].
Additionally, MSCs that are pre-stimulated by macrophage-secreted TNF-α and IFN-γ
release immunosuppressive factors, such as IDO enzyme [148-150], PGE2 and TSG6
[151], and these factors drive pro-inflammatory monocytes towards an anti-inflammatory
M2 state [152, 153]. Beyond their immunomodulatory effects, MSCs are effective at
driving angiogenesis [154, 155] and multilineage differentiation [156, 157] to further
promote repair to damaged tissues. Through the cooperative action of these mechanisms
for MSC action, the introduction of MSCs into the heart has been effective in promoting
cardiovascular function and limiting the expansion of the scarred tissue following MI [158,
159].
Direct MSC injection into the healthy tissue surrounding the infarct concentrates
these therapeutic cells at the site of injury to promote a localized therapeutic effect [160].
Unfortunately, the injected cells are rapidly cleared from the injection site, limiting their
opportunity to modulate the infarct environment. For most injected cell therapies, the vast
majority of the injected cells are rapidly lost from the injection site [161-164] owing to the
injected cells and buffer swelling the tissue. The elastic recovery of the heart tissue drives
fluid escape from the tissue, and the injected cells are swept away [164]. This pressure
driven flow is further exacerbated by heart muscle contractions and other tissue dynamics
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in a pumping heart [165-168]. In MSC therapies for MI, these factors combine to yield as
little as 0.44% of the injected MSCs remaining in the heart 4 days after injection [169].
Since a larger MSC dose carries a greater risk of mortality [170, 171], the maximum
number of MSCs present in the heart post-MI is fundamentally limited by the retention of
these cells in the peri-infarct tissue. The loss of cells from the infarct site is a critical
challenge for the future of MSC-based cardiovascular therapies [164].
We seek to increase the number of MSCs retained in the peri-infarct tissue through
engineering of the MSC peripheral membrane. Our strategy is to present artificial ligands
on the MSC plasma membrane to increase adhesion of the MSC to the peri-infarct tissue.
The inflammatory response to ischemia drives the secretion of proinflammatory factors
which alter the endothelium to recruit leukocytes and other immune cells. The inflamed
endothelium overexpresses CAMs, making these CAM-exposed endothelium sheets
important pathological targets [122-124].
Here, we developed a cell surface coating to present antibodies against ICAM1 to
adhere to the endothelium of infarcted hearts (Figure 5.1a). Through intramyocardial
injection, we confirmed that the delivery of antibody-coated MSCs provides 3-fold higher
retention in infarcted heart tissues when compared to uncoated MSC injection. The
ICAM1 adhesion mechanism is supported through the increased cell adhesion of coated
MSCs to activated endothelial cells and ICAM1-coated glass under physiological shears.
Interestingly, we found that the adhesion of cells was improved with lower concentration
of our biotinylation reagents. Lower concentration of NHS-ester biotin (0.1mM) retained
50% of the cells under wall shear stresses of 150 dyne/cm 2 while no cells were retained
with 1.0 mM biotinylation. In all, this straightforward coating design significantly
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enhances the adhesion of MSCs to an infarcted heart through specific targeting of
overexpression of endothelial ICAM1 in response to local inflammation.

5.3

Experimental section
5.3.1
Mouse

MSCs

MSC isolation and culture

isolated

from

C57BL/6

or

C57BL/6-Tg

(CAG-

EGFP)131Osb/LeySopJ mice (Jackson Laboratory, BarHarbor, ME). Mice were
sacrificed, femurs, tibias and hip bones were collected and then flushed with PBS
supplemented with 10% FBS. MSCs used in this study were of a passage less than 10.
MSCs were cultured in pre-warmed mouse MesenCult TM basal medium, supplemented
with MesenCult™ 10X Supplement (STEMCELL Technologies), 10% USDA Approved
Origin FBS (VWR), 1% 200mM L-glutamine (Gibco) and 1% streptomycin/penicillin
(Gibco). MesenPureTM (STEMCELL Technologies) was added in MSC medium at 1:1000
dilution right before cell seeding. MSCs were cultured under hypoxic conditions (less than
5% O2 supply) for MSC cultivation was needed by introducing ultrapure nitrogen into a
37ºC humidified incubator, with 5% CO2. For cell collection, cells were rinsed with sterile
PBS (Corning) and treated with 0.25% trypsin/EDTA (Gibco) for 5 min in 37ºC. Serumcontaining medium was added to neutralize the trypsin. Cells were centrifuged at 300 g
for 5 min and the supernatant was removed by pipetting. The cell pellet was washed once
and resuspended in ice-cold DPBS before use.
5.3.2

Preparation of anti-ICAM1 coated MSCs

All incubation steps for cell membrane antibody incorporation were processed on
ice. MSCs were rinsed twice with cold PBS. 0.1 mM or 1.0 mM sulfo-NHS-LC-biotin was
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prepared in PBS immediately before cell incubation, 2 mL of biotin solution per 106 cells
is added for 1 h. Cells were then rinsed twice with PBS, and 2 mL of 25 µg/mL streptavidin
in PBS was added for every million cells for 1 h. The streptavidin coated cells were then
incubated for 1h in 30, 50, or 100 µg/mL biotinylated monoclonal mouse antibody against
human ICAM1 (clone IH4, Invitrogen) or 100 µg/mL biotinylated monoclonal rat
antibody against mouse ICAM1 (clone YN1/1.7.4, Invitrogen) in PBS.
5.3.3

MTT viability assay

Metabolic activity detection depending on mitochondrial function was evaluated
by using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) reagents
(M6494, Invitrogen). A 12mM MTT solution was prepared in PBS (5mg/mL). 50,000 cells
were diluted in 1mL MSC culture medium. 200 μL of cell solution was pipetted into 96
well plate and then incubated with 20 μL of MTT stock for 4 h at 37 °C. Cell supernatant
was removed after centrifuge (1 rpm, 5 minutes) and 200 μL of DMSO was added to
dissolve the reacted product. A plate reader (Biotek, Winooski, VT) was used to examine
the sample absorbance at 570 nm. The percentage of cell viability was determined by
normalizing the sample absorbance with the positive control.
5.3.4

Myocardial infarction surgery and intramyocardial cell transplantation.

Myocardial infarction was induced by permanent left anterior descending artery
(LAD) ligation in 8-10 week female C57BL/6 mice under 1-3% isoflurane anesthesia
using a small animal vaporizer system. Immediately after ligation, the animals were
randomized to receive 25µL of either PBS, MSCs, or anti-ICAM1 modified MSCs
(125,000 cells per 25uL injection per mouse) via intramyocardial injection to the periinfarct region. Pain medications were administrated after surgery for 24-48 hours.
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5.3.5

Immunohistochemistry analysis

The hearts were harvested 3 days after MI and MSC injection. Immediately after
cervical dislocation, the hearts were perfused with cold PBS with 4% paraformaldehyde
and fixed for 24 hours prior to embedding in a paraffin block. 4 m thick heart tissue
sections were used for immunofluorescent analysis of heart for evidence of the GFP +
MSCs. Briefly, heart tissue sections were exposed to pH 6.0 antigen retrieval buffer
(Vector Laboratories, Burlingame CA) following the company protocol. Slides were
blocked with normal goat serum for 16 hours at 4C and stained with primary rabbit antiGFP antibodies (Abcam, Cambridge, United Kingdom) following by incubation with
Alexa 488 secondary goat anti-rabbit antibodies (Abcam, Cambridge, United Kingdom).

5.3.6

Flow Cytometry

Single-cell suspensions were prepared from digested cardiac tissue as previous
described [47]. Briefly, hearts collected 3 days after MI were minced then digested using
a collagenase B (Roche, Indianapolis, IN) and dispase II (Roche, Indianapolis, IN) solution
for 30 minutes at 37°C with mixing every 5 minutes. The heart cell suspensions were
strained using 40 μm strainers (VWR, cat#10199-654) to remove tissue debris and
undigested tissue. Cells were washed with flow buffer with centrifugation (400×g for 10
min at 4 °C) and suspended in Flow Buffer. Cells were stained with eFluor 660 conjugated
anti-GFP antibody (eBioscience, Thermo Fisher Scientific, Waltham MA) and analyzed
using an LSR II (Becton Dickinson) in the University of Kentucky Flow Cytometry Core.
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We utilized FlowJo v10 (FlowJo, FlowJo Ashland OR) software to generate dot plots and
analyze the data.
5.3.7

Macrophage cytokine secretion assay

BMDMs (Bone marrow-derived macrophage) were isolated and differentiated
using previously published protocols [172]. Primary macrophages were derived from bone
marrow cells and cultured for 7 days in DMEM (with 10% L929 cell-conditioned
medium, and 10% fetal bovine serum). For co-culturing, 5x105 BMDMs were seeded into
a twelve-well plate. The next day, 20,000 unmodified MSCs or anti-ICAM1 coated MSCs
were placed into the twelve-well plate with the BMDMs. Co-culture were incubated for 3,
hours with or without 100 ng/mL lipopolysaccharide (LPS-B5, Invivogen) and IFN- (20
ng/ml).
Conditioned media were obtained from BMDMs alone, co-cultured with BM-MSCs,
or anti-ICAM1-coated BM-MSCs as described above. The secreted TNF- and IL-10 in
the conditioned media were evaluated using enzyme-linked immunosorbent assay ELISA
kits (BD OptEIA™) according to the manufacturer instructions.
5.3.8

Endothelial cell culture, activation and shear assays

Human Umbilical Vein Endothelial Cells (HUVEC) (#00191027) was purchased
from Lonza. HUVEC culture medium was prepared by adding 1% streptomycin/penicillin
and EGMTM-2 SingleQuotsTM Supplements (CC-4176) into EGMTM-2 Basal Medium
(CC-3156). The EGMTM-2 SingleQuotsTM Supplements include 2% FBS, 0.2 mL
hydrocortisone, 2 mL hFGF-B, 0.5 mL VEGF, 0.5 mL IGF-1, 0.5 mL ascorbic acid, 0.5
mL hEGF, 0.5 mL GA-1000, and 0.5 mL heparin. Cells were cultured in a 37ºC incubator
with 5% CO2. Cells were rinsed with sterile PBS and detached by TrypLE treatment for 5
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min at 37ºC. The trypsin was neutralized with culture medium and centrifuged at 300 g
for 5 min. The supernatant was removed, and cells were resuspended in pre-warmed
medium or PBS before use or next passage.
To create a HUVEC monolayer on glass slides, attachment factor was used to
enhance HUVEC attachment to the glass. Microscope slides (25mm x 75mm) were placed
in a 50 mL conical tube and pre-sterilized overnight in 70 vol% ethanol and dried before
use. Each sterilized slide was loaded into a well (3x8cm) in a 4-well rectangular dishes
and rinsed twice in PBS. Each slide was incubated with 4 mL 1X attachment factor at 37ºC
for at least 3 h. Excess solution removed and 1x106 of HUVEC in 4 mL EGMTM-2 medium
was seeded directly onto each slide. Each HUVEC-seeded slide was used for MSC
adhesion studies after reaching 95% confluency.
HUVECs were activated through the addition of 4 mL of 10 ng/mL TNF-α in
growth factor and serum-suppled EGM-2 medium directly onto a HUVEC-adhered
microscope slide in a 4 well dish at 37ºC incubator for 5 or 20 h.
ICAM1 expression on adherent HUVECs was qualitatively labeled with 25 µg/mL
biotinylated mouse antibodies against human ICAM1 in PBS for 45 min, rinsed twice with
PBS and stained with 2 µg/mL Alexa647-labeled secondary antibodies against mouse IgG
(Invitrogen) for 45 min. Cells were rinsed in PBS and imaged in the far-red channel of a
Nikon Ti-U Epifluorescent microscope.
In cell-cell adhesion studies, HUVEC cells were stained with calcein red for
tracking. HUVECs were rinsed with serum-free (SF) EGM-2 medium twice. Calcein-red
orange powder was dissolved in 63 µL pure DMSO and stored in -20 ºC before use.
HUVEC slides were incubated with in a 1:1000 dilution of the calcein-red orange stock in
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SF-EGM-2 for 3 min and rinsed twice with SF-EGM-2. Cell slides were blocked with 5%
BSA in SF-EGM-2 at least for 1 hour. For the in vitro shear assays of GFP MSCs on
calcein red stained HUVECs, one milliliter of 0.5x106 cells/mL pipetted onto a slide of
95% confluent HUVEC cells blocked with BSA. The coculture was incubated for 5min at
37ºC. Cells were sheared using a rectangular parallel plate flow chamber from Glycotech
(#31-010) with a 0.01-inch-thick gasket. A vacuum pump was used to seal the device to a
cell-coated slide immersed in PBS. The flow rate of fluid through the chamber was
controlled with a syringe pump (NEWERA, #4000-US) and two 60 mL syringes
withdrawing fluid to pull PBS from a reservoir through the chamber at the indicated flow
rate for 15 s. The fluorescence images of attached GFP-positive MSCs under different
shears and the number of retained cells were counted with ImageJ analysis.
Shear stress acting on the cell was calculated as the wall shear stress under
Newtonian flow in a rectangular cross section based on the following equation (Q= flow
rate, µ= fluid viscosity, H= gap height, W= gap width, τw= shear stress at wall).
𝜏 =
5.3.9

6𝑄𝜇
𝐻 𝑤

Quantitation of cell surface group density

Covalent biotinylation of cell surface proteins was achieved by treating cells with
various concentration of sulfo-NHS-LC-biotin (0.025; 0.1; 0.5; 1; 2 mM). Two milliliters
of sulfo-NHS-LC-biotin solution was used to treat 1x106 cells for 1 hour on ice and rinsed
with ice-cold DPBS twice. One milliliter of 0.5 µg/mL streptavidin-phycoerythrin (SAPE)
mixed with extra streptavidin protein (0, 20, 60, 80 or 90 µg/mL) was used to label 1x10 6
of biotinylated cells for 1hr on ice. After rinsing with ice-cold PBS twice, the fluorescence
of PE-labeled cells was analyzed by flow cytometry in FL2 channel.
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QuantiBRITETM PE was purchased from BD Biosciences is a phycoerythrin (PE)
fluorescence quantitation kit and includes PE calibration beads of known quantity of PE
conjugated per bead. Red PE fluorescence was collected in FL2 channel (585/40 nm
bandpass filter) by flow cytometry. The mean FL2 fluorescence per PE was correlated
from a linear regression and was used for quantitation of PE fluorophore bound to each
cell. The number of available biotin groups on each cell event was calculated through PE
calibration curve (Figure 5.2).
Activated or naïve HUVECs were trypsinized as before and rinsed twice with PBS.
100 µL of 2.5 µg/mL biotinylated human ICAM1 antibody in ice-cold PBS was added for
every 106 HUVECs and incubated for 30 min on ice. After rinsing twice with PBS, cells
were incubated in 500 µL of 0.5 µg/mL SA-PE in PBS. After PBS rinsing, the fluorescence
of surface-anchored PE was analyzed through flow cytometry in FL2 channel, and a
relative measure of ICAM1 per cell was determined using the PE calibration curve (Figure
5.2).
After coating with antibody against human ICAM1, coated MSCs were incubated
with 350 µL of PE-conjugated secondary antibody against mouse for 45 min. The PE
fluorescence acquired by FL2 channel of flow cytometry was compared with calibration
PE curve to determine the number of ICAM1 antibody coated on a cell by the assumption
of 1:1 binding ratio between anti-ICAM1 and secondary antibody.
5.3.10 Preparation of hICAM1-coated slides
Human recombinant ICAM1 protein was reconstituted at 250 µg/mL in sterilized
PBS and stored at 4 ºC before use. The density of hICAM1 protein was estimated by
specifically fluorescent targeting on hICAM1 molecules coated on protein-reactive glass
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surfaces. Eleven concentrations of hICAM1 protein (250; 150; 100; 50; 25; 12,5; 6.25; 4;
2; 1 µg/mL and PBSA negative control) were tested in this study. Epoxide slides were
placed in a lid-covered petri dish, coated with 30µL of hICAM1 protein solution in a 1cm 2
area for 3hr, and then rinsed twice with 0.1% BSA in PBS. ICAM1-immobilized slides
were loaded into a Whatman Chip Clip, blocked with 0.1% BSA for 30 min, and washed
with 1X PBS twice. Each ICAM1-coated area was labeled with 50 µL of 30 µg/mL
biotinylated human ICAM1 antibody for 1 h and rinsed twice with PBS. Biotinylated
immobilized sites were fluorescently tagged through the incubation of 70 µL diluted SACy3 (1:40 in PBS) in each well for 30 min. After rinsing with PBS three times, slides were
dried in a stream of air and scanned in an Affymetrix 428 Microarray Scanner at 30 dB
gain in the Cy3 channel. The number of Cy3 molecules were estimated by Cy3 calibration
curve (Figure 5.3) prepared using a Cy3 calibration slide from Full Moon Biosystems and
image analysis using ImageJ software.
5.3.11 In vitro adhesion of anti-ICAM1 coated MSCs on ICAM1-immobilized
surfaces under shears
A 1 cm by 1 cm region of an epoxy slide was treated with 30 µL of human ICAM1
protein in PBS at 6.25 for 3 h at room temperature in a sealed dish. The protein-coated
slides were blocked with 1 mg/mL BSA in PBS for 30 min. 50 µL of 0.5x10 6 MSCs were
added onto the ICAM1-coated surface for 5 or 45 min at room temperature. Cells were
sheared and counted for 30 s using a rectangular parallel plate flow chamber as described
above.

5.4

Results and discussion
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The direct injection of MSCs into the heart wall has been effective in improving
the function of hearts post-MI. The effective dose of MSCs present in the heart tissue after
injection is a critical limitation, and this study tests the hypothesis that the synthetic
incorporation of antibodies against ICAM1 onto the peripheral membrane of the injected
MSCs will increase the number of MSCs retained at the site of injection. Our strategy is
to first biotinylate MSCs through incubation in 1 mM sulfo-NHS-LC-biotin (NHS-biotin),
then coating the MSC surface through incubation in 25 μg/mL streptavidin, and finally
using the excess biotin binding sites of streptavidin to bind a biotinylated-antibody against
mouse ICAM1 (100 μg/mL) (Figure 5.1b). Since this method targets the post-MI
inflammatory environment, we induced MI in our mice with an established infarct model
where the left anterior descending coronary artery is sutured. The animals are then injected
with either 1.25x105 MSCs in PBS or 1.25x105 anti-ICAM1 coated MSCs in PBS. There
was one injection per heart, 25 μL per injection site, and all injections were into the periinfarct heart wall, and the infarct zone was determined through visual tissue discoloration.
Three days following MI and MSC injection, the mice were sacrificed, and the resident
heart cells were dispersed and analyzed by flow cytometry (Figure 5.4a). Our utilization
of GFP-labeled MSCs injected into a non-GFP host allows for simple determination of the
number of injected cells remaining in the host. The number of the injected MSCs
remaining in the heart on day 3 were significantly higher (p=0.02) for the MSCs coated
with antibodies against ICAM1 (16 ± 3.7 cells/mg) than for the unmodified MSCs (4 ± 1.4
cells/mg, Figure 5.4c). This finding is qualitatively supported through the analysis of tissue
sections from other animals in the study, where GFP + cells are more frequent in peri-infarct
tissue sections from the anti-ICAM1 coated MSCs than the uncoated MSCs (Figure 5.4b).
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In related studies, inflammation-adhesive cell coatings have also been designed on MSCs
by incorporating functional ligands that target endothelial antigens [16-20]. Coatings with
a CAM-specific peptide also allowed MSC to target an inflamed endothelium [134], while
surface incorporation of an ICAM1 antibody enhanced MSC homing to the site of
inflammation by MSC adhesion on ICAM1-upregulated endothelium [135]. Finally,
antibodies against VCAM and addressins have also been used to target inflamed tissues in
a mouse model of inflammatory bowel disease [136]. In all, our study strongly supports
for the first time that the ICAM1 coated MSC are retained in the heart wall more than the
established treatment using unmodified MSCs.
Therapeutic MSCs play multiples biological roles in regenerating new cardiac
tissues, regulating extracellular immune responses, secreting angiogenesis-induced
paracrine factors. Therefore, it is essential that our MSC coating strategy preserves the
biological functions required for MI therapy. We coated MSCs with anti-ICAM1 through
1mM ester-biotin treatment and the viability of coated cells is preliminarily supported
through MTT assays as well as MSC expansion in culture. As compared with uncoated
cells, the MSC viability is not significantly impacted by the anti-ICAM1 coatings (Figure
5.5).
Uncoated MSCs or MSCs coated with anti-ICAM1 were prepared using 0.1 mM or
1 mM NHS-biotin and seeded onto pre-coated tissue flasks in media. After 30 minute of
cell culture, all groups exhibited similar numbers of attached MSCs and similar
morphologies, and these groups were indistinguishable two days after treatment (Figure
5.6), suggesting the minimal interference on MSC expansion. In addition, the intensity of
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the GFP signal in the cells is correlated to viability and protein production, and the GFP
signals were also similar across these groups.
The immunoregulatory function of MSCs is proposed as a dominant mode of
cardioprotection post-MI. Near an infarct, ischemia-induced apoptotic and necrotic
cardiomyocytes secrete pro-inflammatory cytokines which drive macrophages into a proinflammatory phenotype. As demonstrated in vivo and in vitro, the introduction of MSCs
to pro-inflammatory macrophages will reduce the level of pro-inflammatory factors
secreted from macrophages. Here we specifically assay the capacity for our anti-ICAM1
coated MSCs to modulate the inflammatory cytokine secretion through an in vitro
coculture assay with BMDM macrophages.
The macrophage was directly contacted with uncoated MSCs, anti-ICAM1 coated
MSCs or serum alone in LPS/IFN- supplemented medium for 3 h. Under LPS and IFN-
stimulation, macrophages can be stimulated to M1 phenotypes for proinflammatory TNFα secretion [173]. Either the uncoated or anti-ICAM1 coated MSCs cocultured with
inflammatory macrophages showed significant decreased TNF-α secretion profile when
compared to macrophage alone (Figure 5.7a). We also investigated the anti-inflammatory
factor secretion following MSC-macrophage crosstalk. The level of immunosuppressive
IL-10 in the conditioned medium exhibited higher concentration in both macrophageinteracted groups compared with non-MSC-interactive macrophage (Figure 5.7b). Hence,
we can conclude that the immunosuppression effects of MSCs are not adversely influenced
by the coating, and the cytokine section from macrophages can be regulated in an
immunosuppressive manner in a presence of anti-ICAM1 coated MSCs.
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In addition to the preservation of the innate functions of MSCs, we have the power
to tune the biotin density on the surface of the cell and the density of antibodies against
ICAM1 presented on our MSCs. The NHS-biotin molecule non-specifically tethers biotin
groups to amine groups on the MSC’s peripheral membrane. The biotin labeling was
determined by pairing accessible biotins with a streptavidin molecule labeled with
phycoerythrin (PE), and comparing flow cytometric fluorescence of each cell to a
calibration bead of known PE loading (Figure 5.2). By simply controlling the
concentration of the NHS-biotin in buffer, up to ~7,000 biotin/µm2 (Figure 5.8a). This
magnitude compares favorably to our previous reports of loading up to 10,000
molecules/µm2 using a similar NHS-biotin approach [23]. To confirm that there are not
inaccuracies in the magnitude of fluorescence value based on energy transfer between
adjacent molecules [174, 175], we competed out the labeled streptavidin with an unlabeled
streptavidin and found comparable biotin densities as the undiluted streptavidin-PE
labeling.
Antibody density on the MSC surface was estimated using PE-labeled secondary
antibodies against mouse IgG. For an MSC treated with 1 mM NHS-biotin, incubations in
30, 50, or 100 µg/mL of biotinylated antibodies against ICAM1 resulted in up to 23
antibodies/μm2 (Figure 5.8b). While ~1 PE is bound per secondary antibody, each primary
antibody will be tagged by multiple secondary antibodies [176]. As a result, the actual
density of anti-ICAM1 groups is likely several fold lower. The biotin density (~7,000
biotin/µm2) represents an upper limit for number of antibodies loaded onto the MSC
surface. Given the larger size of the antibody (150kDa) [177] over the streptavidin (53
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kDa) [178] and inefficiencies of sequential binding, it is reasonable there are order several
orders of magnitude fewer antibodies than accessible biotin groups.
Our overall MSC retention hypothesis is based on the expectation that the antiICAM1 coated MSCs adhere strongly to the ICAM1 presented by the inflamed
endothelium present near the infarct site (Figure 5.1b). To support these proposed
mechanisms, we contrasted the force of adhesion between anti-ICAM1 coated MSCs and
an activated endothelial cell with the shear stress exerted by a flowing buffer (Figure 5.9a).
A near-confluent layer of HUVECs were grown on a microscope slide and were activated
with a 5 or 20h exposure for TNF-α, and activation was confirmed with fluorescent
labeling of ICAM1 on HUVECs (Figure 5.10 and 5.11). MSCs were treated with 0.1 mM
NHS-biotin, streptavidin, and 100 μg/mL biotinylated antibodies against human ICAM1.
MSCs were allowed to settle on the HUVECs for 5 minutes and then subjected to wall
shear stress up to 31 dyne/cm2. While greater shear stresses than 31 dyne/cm2 delaminated
the HUVECs, the chosen shear range captures most of the physiological wall shear stress
range observed in human arteries (10-70 dyne/cm2), veins (1-10 dyne/cm2) and capillary
beds (<1 dyne/cm2) [168, 179-181]. For all shear stresses studied, a greater number of the
anti-ICAM1 coated MSCs were retained on the activated HUVEC cells than unmodified
MSCs (Figure 5.9b and 5.9c). The retention of anti-ICAM1 coated MSCs was comparable
with 5 or 20 h exposure to TNF-α. This is attributed to the surface density of ICAM1 on
the activated HUVECs being in large excess (>500 ICAM1/μm 2, Figure 5.11) compared
to the surface density of the anti-ICAM1 ligands on the MSCs (<23 antibodies/μm 2). In
the absence of TNF-α induced ICAM1 activation, neither the anti-ICAM1 coated MSCs
or the unmodified MSCs were retained on the HUVEC surface under flow. This is
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expected as MSCs do not typically interact with endothelial cells through direct physical
interactions. The statistically insignificant increase in mean retention of the anti-ICAM1
coated MSCs over uncoated MSCs on non-activated HUVECs is potentially attributed to
the low basal expression of ICAM1 on HUVECs is <10 ICAM1/μm 2, Figure 5.11). While
specificity is not required for this application, the antibody-driven mechanism of retention
is expected to be specific. These in vitro shear studies on activated HUVECs support the
proposed antibody-antigen mode of retention as the driver for the increased MSC retention
in vivo.
To further confirm the proposed mechanism for MSC retention, we evaluated cell
adhesion to an ICAM1-coated surface under shearing flow (Figure 5.12a). Epoxy coated
glass slides were incubated in human ICAM1, and the density of ICAM1 on the glass
surface was determined through fluorescent labeling of ICAM1, and correlation of
fluorescent intensity to a calibration slide in a microarray scanner. This approach provided
surface densities of purified protein to 5,000 ICAM1/μm2 (Figure 5.12b), and this range
encompasses the surface density of ICAM1 on non-activated and activated HUVEC cells
(Figure 5.11). In particular, we focused on incubations of 6.25 μg ICAM1/mL to give a
surface density of 2,400 ICAM1/µm2 to replicate the surface density of HUVECs activated
with 20 h exposure to TNF-α (1,500 ICAM1/µm 2). MSCs were added to the ICAM1
surfaces, incubated for 5 minutes at 37ºC, and subjected to shearing flows. For all groups
of anti-ICAM1 coated MSCs, the majority of the cells remained adhered for the expected
physiological range of wall shear stress (<70 dyne/cm2). Increasing the contact time
between the MSC and the ICAM1 surfaces to 45 minutes did not have a significant
increase in the fractional retention of cells, suggesting the adhesion is dominated by rapid
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binding events, including the expected antibody-antigen interactions. Importantly, the
fractional retention of anti-ICAM1 coated MSCs on the purified ICAM1 surface compares
favorably with the fractional retention of for anti-ICAM1 coated MSCs on the activated
HUVECs. These two systems were run using the same MSC-surface contact times, antigen
type, and antigen density. The quantitative agreement in MSC retention supports the
antibody-antigen mode of retention in the HUVEC study, and by extension supports the
role of antibody coatings in the increase in anti-ICAM1 coated cell retention in vivo. We
were unable to retain any uncoated MSCs on the ICAM1 coated surface under the most
minimal shear (Figure 5.13 and 5.14), and this supports our significant differences between
coated and uncoated cells in vivo, and in the in vitro assay of MSC attachment to activated
endothelial cells.
Throughout our in vitro shear assays, MSCs that were biotinylated using 1 mM
NHS-biotin were retained to a lesser degree than the MSCs that were biotinylated using
0.1 mM NHS-biotin (Figure 5.9c and 5.12c). This is counter intuitive, given the higher
ligand density resulting from the 1mM NHS-biotin treatment. Given the necrosis
associated with >1 mM NHS-biotin [182], we suspect this higher concentration is causing
damage to the MSCs which we are not able to detect through viability, proliferation, or
function assays. It is reasonable to think that excessive conjugation of cell surface proteins
will have a significant impact on the function of these proteins. The shear assays of coated
cells on purified surfaces of ICAM1 (Figure 5.12c) still support the antibody-antigen
mechanism, but the magnitude of the effect is lower with the 1 mM NHS-biotin than for
the 0.1 mM NHS-biotin.

5.5

Conclusions
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Direct injection of cells is commonly thought of as a reasonable method of directly
controlling the position of cells in vivo. But on its own, direct injection is not capable of
retaining the majority of these cells at the injection site across multiple clinical applications
[164, 183-186]. While other studies have demonstrated ICAM1 based retention of cells in
inflammatory bowel disease [136], this study is the first direct evidence that anti-ICAM
coatings increase the number MSCs retained in the heart tissue following a heart attack.
We support the in vivo retention phenomenon with a mechanistic study of the adhesion of
the cells when subjected to fluidic shears. The anti-ICAM coating significantly increases
the number of cells retained on activated endothelial cells. To eliminate other cellular
processes, we further supported this mechanism by coating microscope slides with ICAM1
protein and demonstrated the enhanced retention of the anti-ICAM1 coated MSCs over
unmodified MSCs. In all, we connected the design of a cell’s surface can significantly
increase the number of MSCs remaining in a post-infarct heart by promoting strong
adhesion between the MSC and ICAM1 presented by the inflamed endothelium. More
broadly, this study is additional evidence that the intentional engineering of a cell’s
peripheral membrane is an effective strategy for improving the localization of injected
cells in the ever-expanding range of emerging cell-based therapies proposed in modern
medicine.
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Figure 5-1. Scheme of intramyocardial delivery of antibody-coated MSCs. (a) Direct
intramyocardial injection of antibody-coated MSCs and subsequent interaction of MSCs
with inflamed endothelium. (b) Incorporation of inflammation-targeted antibody on MSCs
through biotin-streptavidin affinity.
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Figure 5-2. Standard calibration curve of PE quantitative beads.
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Figure 5-4. In vivo Intramyocardial delivery of ICAM1 antibody-coated MSCs in
infarcted mouse model. (a) Timeline of MI induction, MSC injection and sample
collection. The coated or uncoated cells were directly injected into peri-infarct area
immediately after left anterior descending artery ligation. At day 3, the heart sample was
collected and digested for flow cytometry and immunohistochemistry analysis. (b)
Representative immunofluorescent analysis of uncoated and anti-ICAM1 coated GFPMSCs retention in infarcted heart tissues. The scale bar is 20 µm. (c) Quantitative retention
analysis of uncoated MSCs and anti-ICAM1-coated MSCs through flow cytometry. Data
are presented as mean number of retained MSCs with stand errors (n=4 for uncoated cells
and n=3 for anti-ICAM1 coated MSCs).
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Figure 5-5. Cell viability of anti-ICAM1 coated cells (n=4).
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Figure 5-6. Cell attachment after anti-ICAM1 coating on GFP + MSCs. The scale bar
is 100 µm.
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Figure 5-7. Immunosuppressive cytokine secretion from macrophage-interacted
MSCs.
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Figure 5-8. Quantitation of surface biotin density on biotinylated MSCs. (a)
Quantitation of biotin groups through competitive binding of SA/SAPE on biotinylated
cells. The ester-biotin treated cells were stained with four different ratios of SA to SAPE
(n ≥3). (b) Quantitation of ICAM1 antibodies on the MSC surface with different antibody
concentrations (30, 50 and 100 µg/mL) through secondary PE labeling (n ≥3). The scale
bar is 100 µm.
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Figure 5-9. Cell adhesion on ICAM1-expressed endothelium and cell detachment
under the presence of shear flow. (a) Schematic diagram of experimental setup of sheardetached cells on HUVEC monolayer. (b) Fluorescence images of adhesion behavior of
uncoated or anti-ICAM1 coated MSCs (GFP +) on untreated or TNF-α-treated HUVECs
(calcein-red staining) under shear flow. The anti-ICAM1 coated cells were treated with
0.1mM or 1mM ester-biotin, respectively. Cell adhesion behavior was observed before and
after shear (3dyne/cm2). The scale bar is 100 μm. (c) Relationship between cell retention
% and shear stress under different cell adhesion conditions (n ≥5).
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Figure 5-10. Immunostaining of human ICAM1 protein on non-treated or TNF-α
treated HUVECs. The scale bar is 100 µm.
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Figure 5-11. Quantitative analysis of ICAM1 surface density on non-treated, 5hr
TNF-α-treated, or 20hr TNF-α-treated HUVECs by flow cytometry (n=3).
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Figure 5-12. Cell adhesion on ICAM1-modifed glass and cell detachment under the
presence of shear flow. (a) Schematic diagram of experimental setup of shear-detached
cells on ICAM1-modifed glass. (b) Relationship of human ICAM1 protein density and
protein concentration used for epoxide glass modification (n=3). (c) Relationship between
attached cells % and shear stress under different cell adhesion conditions (n ≥4).
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Figure 5-13. Stationery adhesion of anti-ICAM1 coated MSC on hICAM1-modified
glass. The scale bar is 100 µm.
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Figure 5-14. Stationery adhesion of anti-ICAM1 coated or uncoated MSCs on
ICAM1-modified glass. Data are mean adhered cell numbers with stand errors (n
≥10).
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CHAPTER 6. INTRAVENOUS TARGETING OF MSCS TO MODULATE POST-INFARCT
INFLAMMATION

6.1

Introduction
Insufficient MSC homing to targeted inflammation in AMI-induced heart

represents one of the most critical challenges in regenerative therapy. Targeted cell
delivery appears to be a promising solution for MSC retention in the heart. Herein, the
section will demonstrate a cell surface antibody coating on immunosuppressive MSCs for
inflamed tissue targeting. Initially, by using flow cytometry, the feasibility to coat cells
with ICAM1 antibody was evaluated by surface group quantitation. The adhesion efficacy
of coated cells is correlated to antigen presence on ICAM1-modified surfaces. By
introducing shear flow, I examined the adhesion force present by this antibody-coated
cells. The optimal adhesion efficacy of coated cells was proposed in this study by
biotinylating cells with 0.1mM sulfo-NHS-LC-biotin. One day after the cell injection
through retro-orbital vein, the flow cytometry results showed higher coated MSC
accumulation in the heart, spleen and lung, as compared to uncoated MSCs. By quantifying
immune cells such as neutrophil, monocyte, leukocyte and macrophages in the heart
tissues, the intravenous delivery of anti-ICAM1 coated cells exhibited the dramatically
reduced post-MI inflammation responses.

6.2

Background
Despite significant advances in rapid clinical interventions, acute myocardial

infarction (AMI) is still plagued by high prevalence, morbidity and mortality. The majority
of clinical progress centers on the rapid clearance of obstruction and the prevention of
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restenosis. Critically, the processes responsible for the progressive loss of functional heart
tissue have already initiated. This initial site of damage kicks off a cascade of inflammation
that gradually expands the infarct to encompass large sections of the myocardium,
resulting in tissue fibrosis, ventricular remodeling, heart dilation [187, 188]. Infarct
expansion and heart’s negligible capacity for regeneration leads to an irreversible loss of
function and an increased risk of heart failure.
The prevention of infarct expansion is an exciting path to improve cardiovascular
function post-AMI. Apoptotic cells release many factors which activate inflammatory cells
and lead to the abundant production of pro-inflammatory cytokines. This inflammation
damages nearby healthy tissue and expands the infarct. Mesenchymal stem cells (MSCs)
are potent modulators of inflammation[189-191]. The inflammatory signal cascade
triggers the MSCs to release immunosuppressive factors and growth factors [189, 192194]. The implantation of MSCs near infarcted tissue has slowed the progression of infarct
expansion and improved cardiovascular function. Additionally, implanted MSCs have
some capacity for regeneration through differentiation into endothelial cells, smooth
muscle cells, and cardiomyocytes [111, 112, 118, 169, 195-201]. In all, the implantation
of MSCs is promising for protecting the heart from damage post-AMI and repairing
cardiovascular tissue.
The most effective mode of MSC implantation post-AMI is the direct injection of
cells into the heart wall adjacent to the infarct. The precision of an intramyocardial
injection is unsurpassed for localized MSC delivery, and this strategy has been effective
in numerous animal studies [91, 202, 203]. Critically, direct injection into the wall of a
beating heart in humans requires opening of the chest cavity, and the risk associated with
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this invasive procedure is clinically prohibitive. As a result, most clinical studies sacrifice
the localization of intramyocardial injection for intravenous (IV) injections with minimal
targeting of MSCs to the target tissue [160, 161, 204-206]. With IV injections, MSCs
typically distribute to the lungs and spleen [161, 163, 204].
Here, we demonstrate a simple cell surface engineering strategy to home IV
injected MSCs to an infarct site through inflammation targeting (Figure 6.1). The
inflammation that drives unfavorable expansion of the infarct actively recruits leucocytes
through the expression of ICAM1 on endothelial cells. We create MSCs that are coated
with antibodies against ICAM1 to mimic leucocyte recruitment and support the retention
of MSCs in the inflamed myocardium. To create a cell with an ICAM1-targeting capacity,
we covalently biotinylated cell surface proteins with sulfo-NHS-biotin, and then deposited
a layer of streptavidin to anchor subsequent additions of biotin mouse ICAM1 antibody
onto the MSC’s peripheral membrane. We hypothesize that the antibody coated cells will
adhere to ICAM1 and that more IV administered ICAM1 cells when coated with antibodies
against ICAM1. We test these hypotheses using an established mouse model of AMI, and
then support the in vivo findings with microfluidic in vitro analysis. The antibody coated
MSCs are retained on surfaces of mouse ICAM1 and in the infarcted mouse heart more
than unmodified MSCs. Further, there is a decrease in the number of neutrophils,
leukocyte, macrophage and monocytes in the infarcted hearts when antibody coated cells
were administered over unmodified MSCs. While targeting of cells has been applied to
other inflammatory conditions [135, 136], this work is the first ICAM1 targeting of cells
to effectively modulate the immune environment of the post-AMI heart.

6.3

Experimental section
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6.3.1

MSC isolation and culture

Mouse mesenchymal stem cells (MSCs) isolated from C57BL/6 or C57BL/6-Tg
(CAG-EGFP)131Osb/LeySopJ mice (Jackson Laboratory, BarHarbor, ME). After the
mice were sacrificed, femurs, tibias and hip bones were collected and then flushed with
PBS supplemented with 10% FBS. MSCs used in this study were of a passage less than
10. MSCs were cultured in pre-warmed mouse MesenCultTM basal medium, supplemented
with MesenCult™ 10X Supplement (STEMCELL Technologies), 10% USDA Approved
Origin FBS (VWR), 1% 200mM L-glutamine (Gibco) and 1% streptomycin/penicillin
(Gibco). MesenPureTM (STEMCELL Technologies) was added in MSC medium at 1:1000
dilution right before cell seeding. MSCs were cultured under hypoxic conditions (less than
5% O2 supply) for MSC cultivation was needed by introducing ultrapure nitrogen into a
37ºC humidified incubator, with 5% CO2. For cell collection, cells were rinsed with sterile
DPBS (Corning) and treated with 0.25% trypsin/EDTA (Gibco) for 5 min in 37ºC. Serumcontaining medium was added to neutralize the trypsin. Cells were centrifuged at 300 g
for 5 min and the supernatant was removed by pipetting. The cell pellet was washed once
and resuspended in ice-cold phosphate buffered saline (PBS) buffer (Gibco) before use.
6.3.2

Preparation and surface group quantitation of anti-ICAM1 coated MSCs
All incubation steps for cell membrane antibody incorporation were processed on

ice. MSCs were rinsed twice with cold PBS. 0.1 mM or 1 mM sulfo-NHS-LC-biotin was
prepared in PBS immediately before cell incubation, 2 mL of biotin solution per million
cells is added for 1 h. Cells were then rinsed twice with PBS, and 2 mL of 25 µg/mL
streptavidin in PBS was added for every million cells for 1 h. The streptavidin coated cells
were then incubated for 1h in 30, 50, or 100 µg/mL biotin monoclonal rat antibody against
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mouse ICAM1 (clone YN1/1.7.4, Invitrogen) in PBS. For intravenous injection, cells were
treated with 0.1 mM sulfo-NHS-LC-biotin, 25 µg/mL streptavidin and then 100 µg/mL
anti-ICAM1.
QuantiBRITETM PE tubes purchased from BD Biosciences is a phycoerythrin (PE)
fluorescence quantitation kit and includes PE quantitative beads presenting different
fluorescence intensity levels with the given information of corresponding number of PE
conjugated per bead. PE fluorescence was collected in the FL2 channel (filtered by 585/40
bandpass wavelength) by flow cytometry. The calibration curve of mean FL2 fluorescence
per PE was plotted, and the linear regression equation was used for quantitation of PE
fluorophore bound to each cell (Figure 6.2).
MSC-associated antibody was stained by 2 µg/mL of mouse PE-conjugated
secondary antibody against rat (clone R2B-7C3, Invitrogen). PE fluorescence was
acquired by FL2 channel in flow cytometry. By assuming the binding ratio of PE,
secondary antibody and primary ICAM1 antibody is 1:1:1, the number of ICAM1 antibody
coated on each MSC is estimated by the calibration curve (Figure 6.2).
6.3.3

Cell attachment and MTT viability assay

After anti-ICAM1 coating, 0.1x106 coated cells were cultured in a 12.5 cm2 tissue
culture flask with MSC expansion medium for 2 days. Attachment behavior, cell
expansion and GFP fluorescence of coated GFP+ MSCs was observed with epifluorescent
microscopy.
Metabolic activity detection depending on mitochondrial function was evaluated
by using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) reagents
(M6494, Invitrogen). A 12mM MTT solution was prepared in PBS (5mg/mL). 50,000 cells
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were diluted in 1mL MSC medium. 200 μL of cell solution was pipetted into 96 well plate
and incubated with 20 μL of MTT stock for 4 h at 37 °C. Cell supernatant was removed
after centrifuge (1 rpm, 5 minutes) and 200 μL of DMSO was added to dissolve the reacted
product. A plate reader (Biotek, Winooski, VT) was used to examine the sample
absorbance at 570 nm. The percentage of cell viability was determined by normalizing the
sample absorbance with the positive control.
6.3.4

Preparation and ICAM1 quantitation of mouse ICAM1-coated slides

Recombinant mouse ICAM-1/CD54 Fc chimera protein (796-IC, R&D systems)
was reconstituted at 250 µg/mL in sterilized PBS and stored at 4 ºC before use. The density
of mouse ICAM1 protein was estimated by specifically fluorescent targeting on mICAM1
molecules coated on protein-reactive glass surfaces. Twelve concentrations of mICAM1
protein (100; 50; 25; 12,5; 6.25; 4; 2; 1; 0.5; 0.25; 0.1 µg/mL and PBSA negative control)
were tested in this study. Epoxide slides were placed in a lid-covered petri dish, coated
with 30 µL of mICAM1 protein solution in a 1cm 2 area for 3 h, and then rinsed twice with
0.1% BSA in PBS. ICAM1-immobilized slides were loaded into Whatman Chip Clip,
blocked with 0.1% BSA for 30 min, and washed with 1X PBS twice. Each ICAM1-coated
area was labeled with 50 µL of 30 µg/mL biotinylated mouse ICAM1 antibody for 1 h and
rinsed twice with PBS. Biotinylated immobilized sites were fluorescently tagged through
the incubation of 70 µL diluted SA-Cy3 (1:40 in PBS) in each well for 30 min. After
rinsing with PBS three times, slides were dried in a stream of air and scanned in an
Affymetrix 428 Microarray Scanner at 30 dB gain in the Cy3 channel. The number of Cy3
molecules were estimated by Cy3 calibration curve (Figure 6.3) prepared using a Cy3
calibration slide from Full Moon Biosystems and image analysis using Image J software.
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6.3.5

Laminar flow chamber assay

A 1 cm by 1 cm region of an epoxy slide was treated with 50 µL of mouse ICAM1
protein in PBS (0.1; 1; 6.25; 100; 250 µg per mL) for 3h at room temperature in a sealed
dish. The protein-coated slides were blocked with 1 mg/mL BSA in PBS for 30 min. 50
µL of 0.5x106 coated or uncoated MSCs were added onto the mICAM1-coated surface for
45 min at room temperature.
To assemble the flow chamber system, a parallel laminar flow chamber from
Glycotech (#31-010) was flipped upside down with a 0.01-inch-thick gasket tightly
mounted on the chamber bottom. In this microfluidic chamber, tubing is connected to the
inflow port from a PBS-filled reservoir. The tubing from the outflow port was connected
to two 60 mL syringes on a two-channel syringe pump (NEWERA, #4000-US). Additional
tubing was connected to a vacuum pump to secure the device to the sample slide. The
entire gasket area on the slide was covered with PBS, the sample slide was then gently and
parallelly covered, to avoid bubble formation in the device. The vacuum pump then
secured the slide to the microfluidic device. To introduce laminar flow, the syringe pump
was turned on to pull the liquid into the system at various flow rates. GFP-cells were
sheared for 30 s, and the number of cells remaining on the slide were counted using
ImageJ.
6.3.6

Myocardial infarction surgery and Intravenous MSC delivery

MI surgery was performed as previously described [47]. Briefly, 8-10-week female
C57BL/6 mice were anesthetized under 1-3% isoflurane using a small animal vaporizer
system. MI was induced by permanent left anterior descending artery (LAD) ligation. Two
hours after MI surgery, mice were randomized to receive 100uL of either PBS, MSCs, or
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anti-ICAM1 modified MSCs (1x106 cells per injection per mouse) via intravenous
injection. Pain medications were administrated after surgery for 24-48 hours.
6.3.7

MSC in heart, spleen and lung and inflammatory cells in infarcted heart

Single-cell suspensions for flow cytometry analysis were prepared from digested
cardiac tissue as previous described [47]. Briefly, hearts and lungs collected 1 day after MI
were minced then digested using a collagenase B (Roche, Indianapolis, IN) and dispase II
(Roche, Indianapolis, IN) solution for 30 minutes at 37°C with mixing every 5 minutes.
The cell suspensions in the heart, lung and spleen were strained using 40 μm strainers
(VWR, cat#10199-654) to remove tissue debris and undigested tissue. Cells were washed
with flow buffer with centrifugation (400×g for 10 min at 4 °C) and suspended in Flow
Buffer. Retained GFP+ MSCs were stained with eFluor 660 conjugated anti-GFP antibody
(eBioscience, Thermo Fisher Scientific, Waltham MA) and analyzed using an LSR II
(Becton Dickinson) in the University of Kentucky Flow Cytometry Core. For cardiac
inflammatory cells, antibodies against Ly6G/C (BD Pharmingen), CD45 (Biolegend),
CD115 (Biolegend), CD11b (Biolegend), and F4/80 (Biolegend) were used to identify
inflammatory neutrophils, macrophage, leukocyte and monocytes. We utilized FlowJo v10
(FlowJo, FlowJo Ashland OR) software to generate dot plots and analyze the data.

6.4

Results and discussion
IV injection is a simple and minimally invasive route for MSC delivery, but the

poor recruitment of MSCs to the heart limits the efficacy of IV administration. Our strategy
to increase the MSC population in the heart is to coat the MSCs with antibodies against
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vascular inflammation associated markers (ICAM1) and allow these cells to naturally
home to the ICAM1 upregulation surrounding the infarct.
Our approach for anti-ICAM1 cell coatings is to use the multivalence of
streptavidin to connect a biotinylated cell surface to a biotinylated antibody. The cell
surface is biotinylated with incubation of MSCs in 0.1 mM or 1 mM sulfo-NHS-biotin for
1 hr. The biotinylated cells are then incubated in 25 μg/mL streptavidin, and then in
biotinylated antibodies against mouse ICAM1. The number of antibodies on the cell
surface was estimated by fluorescently tagging the anti-ICAM1 with secondary antibodies
and relating the measured PE fluorescence to a calibration curve of fluorescence per PE.
The resulting number of PE per cell are considered an order of magnitude estimate of the
number of anti-ICAM1 on the cell surface and dividing by a mean cell surface area
provides an estimate of antibody density in our coatings. We first modified cells with 0.1
mM or 1 mM NHS-ester biotin, and then examined coating efficiency by using three
biotinylated anti-ICAM1 concentration (30, 50 and 100 µg/mL) after streptavidin
deposition. Interestingly, cell coating through 0.1 mM biotinylation had higher antiICAM1 surface density than 1 mM biotin coated cells. The process using 0.1 mM
biotinylation delivered up to 74 ± 6.38 anti-ICAM1/µm2 when streptavidin coated cells
are incubated with 100 µg/mL biotinylated antibody (Figure 6.4a). There is a positive trend
of antibody density with the concentration of the biotinylated antibody between 30 and
100 µg/mL for both 0.1 mM or 1 mM biotinylated groups (Figure 6.4a), and this trend is
also supported qualitatively through epifluorescent imaging (Figure 6.4b).
These coatings do not have a negative impact on the viability, proliferation,
attachment to tissue culture polystyrene, morphology, and immunosuppressive function of
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MSCs. After anti-ICAM1 coating on GFP+ MSCs, the coated and uncoated cells were recultured into medium-contained tissue culture plastics respectively. Under 2 days
observation, all the cell groups showed no difference on cell attachment, morphology, and
cell expansion rate. Additionally, the GFP fluorescence remains the same on both coated
and uncoated cells (Figure 6.5). Moreover, cell viability is the second important indicator
of normal cellular function. In this study, MTT assay was used to evaluate cell health after
coating. The coated MSCs were treated with 0.1mM sulfo-NHS-biotin, 25 µg/mL
streptavidin and 100 µg/mL antibody against mouse ICAM1. As positive control, uncoated
cells were mixed with mitochondrial reactive reagents for metabolic activity
determination. After 4 h MTT incubation, the anti-ICAM1 coated cells showed no
significant influence in cell viability (Figure 6.6), which suggests the feasibility for cells
to maintain their cellular functions after modification.
To support the proposed mechanism of targeting through differential adhesion to
endothelial ICAM1 expression, we quantified adhesion of coated and uncoated MSCs to
surfaces coated with BSA or mouse ICAM1. To mimic the inflamed endothelial surface,
we coated epoxy functionalized microscope slides with purified mouse ICAM1 protein.
The density of ICAM1 that is available for antibody binding was determined with primary
antibodies against-ICAM1 and Cy3-labeled secondary antibodies (Figure 6.7a). Based on
this analysis, up to ~9,000 ICAM1 are available for binding. We tested our system with a
surface marker density as low as 300 ICAM1/ µm2, which is slightly lower than we expect
the ICAM1 density to be on an activated endothelium. While direct analysis of ICAM1
density on the inflamed mouse endothelium is not available, surface marker densities on
endothelial cells rarely reach 104 markers/μm2 [207]. These ICAM1-coated surfaces were
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contacted with anti-ICAM1 coated MSCs treated with two different biotinylation
conditions (0.1 mM and 1 mM biotin) and then subjected to laminar shear flow using a
microfluidic chamber. By anti-ICAM1 coating with 0.1 mM biotinylation, the majority of
the antibody coated MSCs were retained on the ICAM1 surfaces with antigen density
higher than 5000 ICAM1/ µm2 for wall shear stresses up to our system limit of 217
dyne/cm2, while very few cells retained with ~300 ICAM1/ µm 2 (Figure 6.7b). On the
other hand, as compared to 0.1 mM biotin-treated cells, the coated cells through 1 mM
biotinylation exhibited overall lower retention efficacy (Figure 6.7c), which also agreed
with the evidence of lower incorporated antibody number on MSC surfaces (Figure 6.4b).
For our target application, around 90% of anti-ICAM1 coated cells were retained under
the 15 dyne/cm2 wall shear stress expected in microvessels adjacent to the infarct site
(Figure 6.7b and 6.7c) [179, 181]. In support of inflammation targeting, negligible
numbers of these same antibody coated MSCs adhered to control surfaces coated with
BSA under any shear stress. In literature, unmodified MSCs are not localized to the
inflammation when injected intravenously [208]. In our in vitro system, the unmodified
MSCs do not adhere in any measurable amount to the ICAM1-coated surface. In all, the
in vitro shear data is supportive of a greater number of antibody-coated cell adhering to
ICAM1-expressing regions than for unmodified cells. Additionally, the antibody coated
cells are expected to specifically target areas of inflammation through a preferential
adhesion to regions of ICAM1-expression.
Based on the higher in vitro retention of anti-ICAM1 coated MSCs through 0.1 mM
biotinylation than 1 mM biotin coated cells, we selected this optimized coating condition
for in vivo intravenous injection. Herein, we anticipated the antibody coated cells would
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specifically target the ICAM1-rich endothelium in the inflamed, post-AMI heart tissue. To
best mimic clinical implementation of MSC therapies post-AMI, we inject the MSCs into
the retro-orbital vein of mice that survived for two hours following AMI by ligation of the
left anterior descending coronary artery. In agreement with clinical injection via a catheter,
the circulatory pathway for retro-orbital injection provides the heart a first opportunity for
heart engraftment prior to encountering the lungs or spleen (Figure 6.8a). The mice were
randomly assigned into three treatment groups (Figure 6.8b): buffer only (n=4; 100 μL 1x
PBS), unmodified MSCs (n=5; 106 cells in 100 μL 1x PBS), and anti-ICAM1 coated MSCs
(n=4; 106 cells in 100 μL 1x PBS). Following 24 h, the mice were sacrificed, and each
heart, lung, and spleen was digested to isolate the cells residing in each organ. The
quantities of injected MSC were identified based on GFP expression in flow cytometry.
The number of MSCs retained in the heart had over 3-fold increase for the antibody coated
cells when compared to the unmodified MSCs (p < 0.05, Figure 6.9a). This supports the
hypothesis that the antibody coating encourages association of the coated MSC with the
inflamed endothelium of the heart.
Interestingly, there was also a significant increase of anti-ICAM1 coated cells (n=3)
being retained in the lungs and the spleen over unmodified cells (n=4; p < 0.01, Figure
6.9b and 6.9c). While MSC retention in the lung and spleen have been reported previously
for unmodified MSCs [167, 209, 210], the increased retention with anti-ICAM1 coatings
suggests the coating is also enhancing the MSC interactions at these sites. While
significant inflammation is not expected at the lung and spleen following AMI, the basal
level of ICAM1 expression on the endothelium may be driving the observed increase in
off-target MSC retention. Additionally, the low shear stress in these capillary-abundant
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organs may also attenuate MSC clearance and drive increased cell accumulation with
minimal increases in adhesion [160].
As a result, we must conclude the antibody coating drives increased retention of
MSCs in a nonspecific manner. Importantly, we still observe a significant modulation of
the peri-infarct immune response with our anti-ICAM1 coated MSCs. Ly6C hi and Cd115
are the markers positive for inflammatory monocyte while Ly6C hi/Cd115- represent
neutrophils. The number of Ly6Chi monocytes in the heart was lower for the anti-ICAM1
MSCs group (n=3) than PBS alone (n=4; P < 0.05, Figure 6.10a) and uncoated cells.
Similarly, neutrophils are a hallmark of the inflammation, and there were significantly
fewer neutrophils in the antibody coated MSC group than only buffer and uncoated cell
injection (n=4; P < 0.05, Figure 6.10b). While there appear to be fewer monocyte,
macrophages or leukocytes present in the antibody coated MSC group, this difference was
not conclusive (P>0.05, Figure 6.10c and 6.10d). In all, the antibody coated group offered
a dramatic reduction of the inflammatory response post-MI.

6.5

Conclusions
Systemic IV administration is a more durable MSC delivery method for clinical

therapy in a minimally invasive manner as compared to direct intramyocardial injection.
Prior intravenous MSC delivery trials represent the modest cardiac improvement by MSCmediated immunomodulation after AMI; however, the rapid clearance of injected cells by
cardiac contraction and circulatory shear flow highly restrict MSC’s therapeutic benefits
in an infarct heart. To enhance the persistence of intravenously delivered MSCs in the
inflamed heart, we demonstrated an ICAM1-targeted coating via biotin-streptavidin
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bridging. The anti-ICAM1 coating significantly strengthened the cell resistance to
physiological shears, supporting the feasibility of coated cells to strongly interact with
post-inflammatory tissues. We support the increase in in vivo MSC homing to the inflamed
heart compared to uncoated cells after cell delivery into circulatory shear blood. More
importantly, the significant attenuation in immune cells activities by the delivery of antiICAM1 coated cells exhibited more effective immunosuppressive effects over nonICAM1-targeted cell groups. In conclusion, this is a first proof-of-concept study to
promote post-AMI immunosuppression by transporting ICAM1-adhesive MSCs to the
targeted site of inflammation via in vivo intravenous injection.
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Figure 6-1. Systemic intravenous injection of therapeutic MSC to the site of
inflammation.
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Figure 6-2. Standard calibration curve of PE quantitation bead.
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Figure 6-4. Quantitation of incorporated antibody on MSCs. (a) Quantitation of
ICAM1 antibodies on the MSC surface with different antibody concentrations (30, 50 and
100 µg/mL) through secondary PE labeling. Cells were coated through 0.1 mM or 1mM
NHS-ester biotinylation (n ≥3). (b) Fluorescence image of antibody-coated cells through 1
mM biotinylation with different antibody concentration after secondary PE antibody
staining. The scale bar is 100 µm.
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Figure 6-5. Cell attachment after antibody coating. The scar bar is 100µm.
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Figure 6-6. Cell viability MTT assay.
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Figure 6-7. Cell adhesion on mouse ICAM1-modifed glass and cell detachment under
the presence of shear flow. (a) Relationship of mouse ICAM1 protein density and protein
concentration used for epoxide glass modification. (b) Cell retention and shear detachment
of coated cells through 0.1 mM biotinylation under different mouse ICAM1 density (n ≥3).
(c) Cell retention and shear detachment of coated cells through 1 mM biotinylation under
different mouse ICAM1 density (n ≥5).
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Figure 6-8. In vivo Intravenous delivery of anti-ICAM1 coated MSCs in infarcted
mouse model. (a) The circulatory pathway of intravenously delivered MSCs through retroorbital injection. (b) Timeline of MI induction, MSC injection and sample collection. The
coated or uncoated cells were intravenously delivered into 2 hours after left anterior
descending artery ligation. One day after injection, the cell samples in the heart, spleen and
lung were collected for quantitative analysis through flow cytometry. The images were
obtained from smart servier medical art (https://smart.servier.com/).
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Figure 6-9. MSC accumulation in heart, spleen and lung. (a) Quantitative retention
analysis of uncoated MSCs and anti-ICAM1-coated MSCs in the heart through flow
cytometry. (b) Quantitative analysis of uncoated MSCs and anti-ICAM1-coated MSCs in
the lung. (c) Quantitative analysis of uncoated MSCs and anti-ICAM1-coated MSCs in the
spleen. Data points are presented as mean cell number, with error bars presenting standard
error (n=4 for uncoated cells and n=3 for anti-ICAM1 coated MSCs).
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Figure 6-10. Immunosuppressive effects in the heart. Cell samples collected from the
heart tissues after PBS, uncoated MSC or anti-ICAM1 coated MSC injection were
quantified through flow cytometry by immunostaining with several antibodies, including
anti-Ly6G/C, anti-CD45, anti-CD115, anti-CD11b and anti-F4/80. (a) Quantitative
analysis of Ly6Chi monocytes in the heart. (b) Quantitative retention analysis of
Ly6Chi/Cd115- neutrophils. (c) Quantitative analysis of Cd11b+ F4/80 cells in the heart. (d)
Quantitative analysis of Cd45+ cells in the heart. Data points are presented as mean cell
number, with error bars presenting standard error (n=4 for uncoated cells and PBS
injection, and n=3 for anti-ICAM1 coated MSCs).
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CHAPTER 7. CONCLUSIONS AND FUTURE PERSPECTIVES
7.1

Conclusions
Cell surface coating provides non-intrinsic biological properties by incorporating

functional biomaterials for transporter cells to specifically interact with their environment.
Based on the diverse molecular structures and unique chemical property of a cell, we are
allowed to specifically characterize cell surface lipids, proteins, and charged molecules
through different modification strategies, including lipid intercalation, electrostatic
deposition, ligand-receptor interaction, antigen-antibody affinity and covalent protein
crosslinking. In this dissertation, we developed cell surface engineering techniques for cell
mediated drug delivery or tissue targeting purposes primarily through covalent NHS-ester
biotin modification.
Initial work in Chapter 3 proposed a method to generate nanoparticle-loaded
polymeric

patch

on

living

cells

through

surface-mediated

photolithographic

polymerization. We photopolymerized a nanothin hydrogel pattern by incorporating
photoinitiator on a biotinylated cell membrane. The fluorescence of fluorophoreencapsulated PEGDA hydrogel created on a photoinitiator-labeled microarray was used to
estimate the film height of less than 100 nm on polymerized cells. The biotinylated
microarray platform that mimicked the polymerization behavior on biotinylated cells
assists us to precisely control the formation of a 10 µm stripe patch pattern by using a
photomask with different irradiation parameters. We observed that the 5 min irradiating
time was an optimized polymerization condition to create a hydrogel patch pattern with the
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least pattern inaccuracy on living cells without affecting cell viability 2 days after
polymerization.
Furthermore, in Chapter 5 and 6 we utilized an inflammation-targeted antibody
coating on MSCs to promote local cell retention in a post-MI heart through intramyocardial
or intravenous delivery route. We coated a layer of biotinylated antibody against human or
mouse ICAM1 protein on a streptavidin-deposited biotinylated cell. Through direct cell
injection into peri-infarct area immediately after the MI induction in mice, examination of
retained cell number in the heart at day 3 from both IHC staining and flow cytometry
indicated the four-time increased retention of anti-ICAM1 coated cells over uncoated ones
showing the enhanced inflammation-sensing ability in the heart. The cells coated through
1mM biotinylation which exhibited ~7000 biotin/µm 2 and 23 anti-ICAM1/µm2 indicated
the available coating condition for cell retention enhancement. In addition, the anti-ICAM1
coated cells showed significantly increased adhesion force on both inflamed endothelium
and ICAM1-modified surfaces in a presence of physiological shears (< 30 dyne/cm 2) as
compared to untreated cells. In Chapter 7, the coated cells were intravenously delivered
through retro-orbital venous in in vivo MI-induced mice model and were then circulated
into flowing blood to reach the post-MI inflamed regions. In contrast to uncoated cells, we
observed ~15-fold increase in coated MSC retention in the heart. The overall increase of
coated MSC accumulation in heart, spleen and lung was also observed, as compared to
uncoated cells or PBS injection, due to the high ICAM1 sensitivity of coated cells to target
capillary network in these organs. More importantly, we also noticed the dramatically
reduced inflammatory activities of multiple immune cells in the heart, including
inflammatory monocytes, macrophages and neutrophils.
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This immunosuppression

outcome supports the improvement of cardiac therapeutic effects by the intravenous
injection of inflammation-recognized MSCs. In conclusion, with our advances in
integration of different material coatings, our strategy using cell surface covalent
biotinylation enables the applications ranging from drug delivery to tissue engineering
potentials.

7.2

Future perspectives
7.2.1

Designing a functional polymer coating for drug delivery

The traditional method to load drug into cell vehicle is through cellular uptake or
internalization of nanocarriers. However, the dynamic intracellular degradation largely
limits the drug stability during delivery. Herein, we have demonstrated cell surface
engineering techniques to introduce a functionalized loading of exogenous biomaterial
encapsulated in a cell-associated patch film. While our technique using photolithographic
polymerization is only applicable in the adherent type of transport cells, such as stem cells,
skeletal fibroblast or macrophage, the use of full surface coating on suspension cells, such
as neutrophils or lymphocytes, is also a developing field for cell-based drug delivery. For
future directions, the polymer coating on living cells can be designed with a desirable
mechanical or biochemical property in a controllable drug release manner. To create a
highly crosslinking polymeric payload with stable and durable drug encapsulation efficacy,
the generation of cell surface polymerized scaffold can be altered by adjusting the reacting
condition during polymerization, the quantity of reacting chains, the type of monomer
crosslinker and the addition of functional conjugation on a polymer chain. Considering the
rapid drug leakage through absorption or physical encapsulation, the particle chemistry of
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encapsulated nanocarrier is an important factor to modulate the controlled release profile
from the cell-coated polymer matrix. For the PEGDA hydrogel coating we generated on
cells, the small mesh size (less than 10nm) allows complete encapsulation of nanoparticles
between 10 and 100 nm in size, including liposomes or polystyrene nanoparticles [54].
With drug-loaded patch or polymer coating, we expect the development of a new
generation of cell-mediated drug delivery that exploits the inherent cellular trafficking
functions for local targeted therapy.
7.2.2

Selection of targeting ligand for tissue-targeted specificity

Our work demonstrated the significant improvement in cell retention and MSCguided immunosuppression by intravenously injecting anti-ICAM1 coated MSCs.
However, the cell entrapment in other organs could interfere the MSC therapeutic
efficiency to rejuvenate local heart function. Hence, to enhance the cell transportation in
the local heart, the selection of pathological targets that mainly express or accumulate in
the infarcted myocardium will be the next exploring topic for ligand or antibody coated
cells to precisely sense the post-MI injured destination. From our work, the key advantage
of cell surface biotin modification is its possibility to incorporate various avidin or
avidin/biotin-associated ligands to fit the applications for different tissue targeting. For
instance, the membrane incorporation of antibody against tumor-specific receptor could
assist the hitchhiking of cytotoxic T cells to attack the tumor-residing area. In the future,
this coating method also provides a non-genetic methodology to apply tumor-recognized
antibody on cytotoxic killer cells for tumor-eliminating applications.
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APPENDIX

APPENDIX 1. A549 cell viability and cytotoxicity assay treated with Sulfo-NHSLC-biotin
The A549 cell line was cultured in RPMI-1640 medium containing 10% fetal
bovine serum (FBS) and 1% streptomycin/penicillin at 37 oC incubator. Glass microscope
slides (25mm x 75mm) were sterilized in a conical tube by ethanol overnight before cell
culturing. After trypsinization with 5mL typsin for 5 minutes, A549 cells were cultured on
the microscope slide with a cell density of 1.5 million cells per slide. After cell culture on
the slides, A549 cells over 80% confluence on microscope slides were placed on ice for 20
min then washed with ice cold PBS three times and loaded into Whatman Chip-Clip. A
45mM Sulfo-NHS-LC-biotin (Thermo Scientific) was prepared in dimethyl sulfoxide no
more than 5 min before incubation Then, cells were treated with 0.5mM, 1mM, 2mM,
4mM or 8mM of sulfo-NHS-LC-biotin solution diluted from stock solution in ice cold PBS
for 20 min. After biotinylation, cells were rinsed with cold PBS twice and incubated with
0.1% calcein (Life Technologies) and 0.2% ethidium (Life Technologies) diluted in PBS+
3%v/v FBS for 30 minutes. Images were observed with epi-fluorescence microscope
(Nikon Eclipse Ti-U) and analyzed by Image J software. Cell viability was calculated by
the following equation: calcein positive cell number / [calcein labelled cell number +
ethidium labelled cell number – calcein/ethidium double labelled cell number].
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Figure A. 1: Calcein/ethidium analysis of sulfo-NHS-LC-biotin treated A549 viability.
After treatment with 0mM, 0.5mM, 1mM, 2mM, 4mM and 8mM sulfo-NHS-LC-biotin,
cells were stained by calcein for viability and ethidium for cell death.
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APPENDIX 2. Microarray of polymerization-based amplification
Epoxy-functionalized slides were dipped in ethanol overnight before microarray
printing for sterilization. Twelve serial dilutions of biotinylated bovine serum albumin
(bBSA, 0.105, 0.262, 0.655, 1.638, 4.096, 10.24, 25.6, 64, 160, 400 and 1000 μg per mL)
coupled with negative control group (0 μg/mLbBSA) were prepared in PBS 1X. The epoxy
slides were printed by Affymetrix 417TM Arrayer, with serial bBSA solutions pipetted into
a 96 well plate. Each concentration of bBSA was duplicated into two spots on the slides.
After drying overnight, the biotinylated epoxy-functionalized slides were loaded in
Whatman Chip-Clip, incubated with 400 μl of 0.1% bovine serum albumin diluted in
phosphate buffered saline (PBSA) in each Chip-Clip array well and covered with foil for
45 minutes. After each well rinsed with PBSA once, 400μl of SA-EITC (25 μg/mL)
solution was added into array well in the absence of light for 30 minutes. After the
conjugation of streptavidin and biotin has finished, each well was rinsed twice with 400 μl
of PBSA with 5 minutes and once with deionized water. 350 μl of precursor monomer
solution (259 µl PEGDA 575, 29 μl triethanolamine and 4.5 μl vinyl pyrollidinone
dissolved in 895 μl deionized water) was pipetted into each well and placed in a clear
plastic bag which has been purged with ultra-pure N2 for 5 minutes. An LED lamp
(Thorlabs M530L2-C1) with peak wavelength of 530 nm was adjusted to 1, 5, 10 or
15mW/cm2 with a radiometer (International Light Technologies (model number
ILT1400A). Polymerization commenced with the LED irradiation under continuous
nitrogen flow for 20 minutes. After photopolymerization, the slides were rinsed with
deionized water and dried overnight. The thickness of polymer film on each array spot was
measured by Dektak 6M profilometer. The scanning parameters of surface profilometry
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measurement were set with scan length of 4200 μm for 40 s, stylus force of 1 mg, and
resolution of 0.350 μm per sample.
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Figure A. 2. Relationship between bBSA concentration and the thickness of PEGDA
hydrogel thickness under different light intensity.
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APPENDIX 3. The setup of photolithographic patch polymerization

Figure A. 3. Photomask assembly for patch polymerization on a biotinylated
microarray or slides of cultured cells. Reprinted from [182], Copyright 2017, with
permission from American Chemical Society.
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APPENDIX 4. Laminar flow chamber assay

Figure A. 4. The setup of laminar flow chamber assay for cell detachment under
shears.
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